Details of the Drug

General Information of Drug (ID: DMSE3I7)

• Drug Name: Gemcitabine
• Synonyms: Gemcitabine hydrochloride; DDFC; DFdC; DFdCyd; Folfugem; GEO; Gamcitabine; GemLip; Gemcel; Gemcin; Gemcitabina; Gemcitabinum; Gemtro; Gemzar; Zefei; Gemcitabine HCl; Gemcitabine stereoisomer; LY 188011; LY188011; Gemcitabina [INN-Spanish]; Gemcitabinum [INN-Latin]; Gemzar (TN); Gemzar (hydrochloride); Inno-D07001; LY-188011; Gemcitabine (USAN/INN)

Indication

Disease Entry	ICD 11	Status	REF
Anterior urethra cancer	N.A.	Approved	[1]
Biliary tract cancer	2C17	Approved	[1]
Carcinoma	2A00-2F9Z	Approved	[1]
Cervical cancer	2C77.0	Approved	[1]
Cholangiocarcinoma	2C12.10	Approved	[1]
Fallopian tube neoplasm	N.A.	Approved	[1]
Gallbladder carcinoma	N.A.	Approved	[1]
Leiomyosarcoma	2B58	Approved	[1]
Leukemia	N.A.	Approved	[1]
Lung cancer	2C25.0	Approved	[1]
MALT lymphoma	N.A.	Approved	[1]
Nodal marginal zone lymphoma	2A85.0	Approved	[1]
Non-small-cell lung cancer	2C25	Approved	[2]
Ovarian disorder	N.A.	Approved	[1]
Ovarian neoplasm	N.A.	Approved	[1]
Pancreatic adenocarcinoma	N.A.	Approved	[1]
Pancreatic ductal carcinoma	2C10.0	Approved	[1]
Pancreatic tumour	2C10	Approved	[1]
Posterior urethra cancer	N.A.	Approved	[1]
Recurrent adult burkitt lymphoma	2A85.6	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Splenic marginal zone lymphoma	N.A.	Approved	[1]
Urethral cancer	2C93	Approved	[1]
Urinary bladder neoplasm	N.A.	Approved	[1]
Middle East Respiratory Syndrome (MERS)	1D64	Preclinical	[4]
Severe acute respiratory syndrome (SARS)	1D65	Preclinical	[4]
Colon cancer	2B90.Z	Investigative	[1]

• Therapeutic Class: Anticancer Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  L01BC05: Gemcitabine
  L01BC: Pyrimidine analogues
  L01B: ANTIMETABOLITES
  L01: ANTINEOPLASTIC AGENTS
  L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 263.2
  Logarithm of the Partition Coefficient (xlogp); -1.5
  Rotatable Bond Count (rotbonds); 2
  Hydrogen Bond Donor Count (hbonddonor); 3
  Hydrogen Bond Acceptor Count (hbondacc); 6
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [5]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 32 mL/min/kg [6]
  Elimination: Within a week following administration of a single dose of 1000 mg/m2 infused over 30 minutes, about 92-98% of the dose was recovered in urine where 89% of the recovered dose was excreted as difluorodeoxyuridine (dFdU) and less than 10% as gemcitabine [7]
  Half-life: The concentration or amount of drug in body reduced by one-half in 0.7 - 1.6 hours [8]
  Metabolism: The drug is metabolized via the deoxycytidine kinase [9]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 93.9 micromolar/kg/day [10]
  Unbound Fraction: The unbound fraction of drug in plasma is 1% [6]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.5 L/kg [6]
  Water Solubility: The ability of drug to dissolve in water is measured as 15 mg/mL [5]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Fatigue	Not Available	ERBB2	OTOAUNCK	[11]
Haematotoxicity	rs11141915	DAPK1	OTNCNUCO	[12]
Neutropenia	rs9609078	OSBP2	OTDGLB4J	[13]
Neutropenia	rs2547917	PDE4D	OT1RWFV0	[13]
Neutropenia	rs12900463	ALPK3	OTLUYSMO	[13]

• Chemical Identifiers:
  Formula: C9H11F2N3O4
  IUPAC Name: 4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
  Canonical SMILES: C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F
  InChI: InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1
  InChIKey: SDUQYLNIPVEERB-QPPQHZFASA-N
• Cross-matching ID:
  PubChem CID: 60750
  ChEBI ID: CHEBI:175901
  CAS Number: 95058-81-4
  UNII: B76N6SBZ8R
  DrugBank ID: DB00441
  TTD ID: D03UVS
  VARIDT ID: DR00063
  INTEDE ID: DR0765
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ribonucleoside-diphosphate reductase M2 (RRM2)	TTBWDI0	RIR2_HUMAN	Modulator	[14]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Concentrative nucleoside transporter 1 (SLC28A1)	DT0EQPW	S28A1_HUMAN	Substrate	[15]
Multidrug resistance-associated protein 5 (ABCC5)	DTYVM24	MRP5_HUMAN	Substrate	[16]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[17]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytidine aminohydrolase (CDA)	DEKEDRC	CDD_HUMAN	Substrate	[18]
Cytidine deaminase (cdd)	DETX3A5	CDD_ECOLI	Substrate	[19]
Cytidine deaminase (cdd)	DEFVABT	CDD_KLEP7	Substrate	[19]
Uridine/cytidine monophosphate kinase (UMPK)	DEMPH4I	KCY_HUMAN	Substrate	[20]
Cytidine deaminase (cdd)	DEYILK4	E0TLJ6_MYCHH	Substrate	[21]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1)	OTG2T749	CP24A_HUMAN	Gene/Protein Processing	[22]
1-acyl-sn-glycerol-3-phosphate acyltransferase beta (AGPAT2)	OT5I4Y9K	PLCB_HUMAN	Gene/Protein Processing	[22]
14-3-3 protein sigma (SFN)	OTLJCZ1U	1433S_HUMAN	Post-Translational Modifications	[23]
3',5'-cyclic-AMP phosphodiesterase 4D (PDE4D)	OT1RWFV0	PDE4D_HUMAN	Drug Response	[13]
3-phosphoinositide-dependent protein kinase 1 (PDPK1)	OTT09ZVP	PDPK1_HUMAN	Drug Response	[24]
5,6-dihydroxyindole-2-carboxylic acid oxidase	OTRK49R4	TYRP1_HUMAN	Gene/Protein Processing	[22]
Adiponectin (ADIPOQ)	OTNX23LE	ADIPO_HUMAN	Gene/Protein Processing	[25]
ADP-ribosylation factor 1 (ARF1)	OT5C4C3L	ARF1_HUMAN	Gene/Protein Processing	[22]
Aldehyde dehydrogenase 1A1 (ALDH1A1)	OTCUWZKB	AL1A1_HUMAN	Gene/Protein Processing	[26]
Alpha-2-macroglobulin (A2M)	OTFTX90K	A2MG_HUMAN	Gene/Protein Processing	[25]

Molecular Expression Atlas of This Drug

• The Studied Disease: Anterior urethra cancer

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Ribonucleoside-diphosphate reductase M2 (RRM2)	DTT	RRM2	1.66E-04	2.66	1.68
Multidrug resistance-associated protein 5 (ABCC5)	DTP	MRP5	8.28E-03	6.40E-01	7.46E-01
P-glycoprotein 1 (ABCB1)	DTP	P-GP	2.74E-01	-2.19E-01	-3.03E-01
Concentrative nucleoside transporter 1 (SLC28A1)	DTP	CNT1	2.99E-02	-3.24E-01	-1.02E+00
Uridine/cytidine monophosphate kinase (UMPK)	DME	CMPK1	2.73E-04	5.37E-01	1.41E+00
Cytidine aminohydrolase (CDA)	DME	CDA	1.62E-05	4.67E-01	8.77E-01

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Bone Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
RPMI-3460/CS1	GDSC1; GDSC2	-0.933	8.7906	-3.4464	32.6592
ES1	GDSC1; GDSC2	-8.0126	-7.0125	-8.0126	68.244
EW-7	GDSC1; GDSC2	-7.788	-6.5276	-7.788	66.8913
EW-1	GDSC1; GDSC2	-7.6597	-5.0621	-7.6599	66.059
EW-22	GDSC1; GDSC2	-7.6488	-5.8011	-7.6488	66.0472
ES4	GDSC1; GDSC2	-7.5375	-5.3677	-7.5376	65.3659
ES8	GDSC1; GDSC2	-7.4939	-6.6504	-7.4939	65.1207
SK-ES-1	GDSC1; GDSC2; CTRP2	-7.0641	-5.7685	-7.0641	66.0533
SK-N-MC	CTRP2	-6.8175	-5.1142	-6.8175	78.9377
ES7	GDSC1; GDSC2	-6.7824	-4.3764	-6.7826	60.8202
SK-PN-DW	GDSC1; GDSC2	-6.6942	-5.3983	-6.6942	60.3059
HuO9	GDSC1; GDSC2	-6.4807	-3.808	-6.4815	58.9957
A-673	GDSC1; GDSC2; CTRP2	-6.4779	-3.6987	-6.4781	62.8246
EW-16	GDSC1; GDSC2	-6.4702	-3.1784	-6.4746	58.8756
TC71	CTRP2	-6.4354	-5.908	-6.4354	76.4802
EW-12	GDSC2	-6.3584	-3.223	-6.3617	88.5908
EW-3	GDSC1; GDSC2	-6.0884	-2.2655	-6.1039	56.539
MHH-ES-1	GDSC1; GDSC2; CTRP2	-6.0366	-3.8394	-6.0366	60.4445
TC-71	GDSC1; GDSC2	-5.7517	-3.9539	-5.7517	54.6305
EW-13	GDSC1; GDSC2	-5.4815	-1.5213	-5.643	41.8484
CADO-ES1	GDSC1; GDSC2	-4.7843	-3.2181	-4.7843	48.8066
HOS	GDSC1; GDSC2; CTRP2	-4.6532	-0.2705	-4.6839	52.8432
NY	GDSC1; GDSC2	-4.6343	0.4659	-4.7803	48.0178
ES6	GDSC1; GDSC2	-3.6578	5.5027	-4.9853	43.9607
EW-11	GDSC1; GDSC2	-2.5526	3.3253	-3.0901	36.7803
MG-63	GDSC1; GDSC2; CTRP2	-1.8685	12.3654	-5.2601	42.5621
SJSA-1	GDSC1; GDSC2; CTRP2	-1.8312	5.7732	-2.6702	39.2569
ES5	GDSC1; GDSC2	-1.0164	12.3126	-5.1549	37.5812
H-EMC-SS	GDSC1; GDSC2	-0.9287	5.7236	-2.1385	29.2909
U2OS	GDSC1; GDSC2; CTRP2; CTRP1	0.4856	6.5902	-0.4246	27.4477
SaOS-2	GDSC1; GDSC2; CTRP2	0.5453	10.9724	-2.1777	31.6547
EW-24	GDSC1; GDSC2	0.7441	8.7748	-1.7671	23.886
EW-18	GDSC1; GDSC2	0.7833	11.0151	-2.8018	26.7715
HuO-3N1	GDSC1; GDSC2	1.5623	9.1168	-1.1467	20.0425
CAL-72	GDSC1; GDSC2	1.9172	14.8831	-3.6673	26.503
Hs 888.T	CTRP2	2.9654	11.989	-0.283	25.6077
CHSA0108	GDSC1; GDSC2	3.2523	11.7033	-0.9269	16.8404
CAL-78	GDSC1; GDSC2; CTRP2	3.5873	12.1747	0.2024	18.8382
CHSA0011	GDSC1; GDSC2	3.7042	9.9268	0.3325	11.3043
CHSA8926	GDSC1; GDSC2	4.5342	11.7305	0.0802	10.2697
U-CH2	GDSC2	5.0728	12.5447	0.0757	14.9161
Hs 822.T	CTRP2	6.1317	7.4868	4.5662	0.6504
G-292 clone A141B1	GDSC1; GDSC2; CTRP2	6.2014	12.8143	2.0765	8.5005
NOS-1 [Human HNSCC]	GDSC1; GDSC2	8.06	19.7374	-1.353	10.4239
SW1353	CTRP2	8.4884	21.4467	-0.494	15.7308

Cancer Drug Sensitivity Data Curated from 218 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JK1	CTRP2	-4.8744	-2.5199	-4.8746	66.0198
MEC1	CTRP2	-4.5433	3.7422	-5.0943	60.4253
JM1	GDSC1; GDSC2; CTRP2	-8.8794	-7.3057	-8.8794	80.1431
MOTN-1	CTRP2	-12.0547	3.2261	-13.1531	78.1257
Hs 611.T	CTRP2	-11.1341	6.989	-13.1786	72.8968
OCI-Ly3	CTRP2	-11.042	-7.7935	-11.042	96.1193
SEM	CTRP2	-9.6282	-8.8009	-9.6282	96.8926
EB1	CTRP2	-9.2791	0.9017	-9.6822	77.603
NU-DHL-1	CTRP2	-9.2517	1.3337	-9.7235	76.896
ATN-1	GDSC1; GDSC2	-8.6305	-7.4623	-8.6305	71.9638
QIMR-WIL	GDSC1; GDSC2	-8.6135	-7.0737	-8.6135	76.2724
Hs 445	GDSC1; GDSC2	-8.5466	-5.7321	-8.5469	71.2717
WSU-DLCL2	GDSC1; GDSC2; CTRP2; CTRP1	-8.5165	-6.6652	-8.5165	73.9604
SU-DHL-5	GDSC1; GDSC2; CTRP1	-8.4243	-7.5024	-8.4243	70.7225
BONNA-12	GDSC2	-8.266	-1.1509	-8.442	85.5036
697	GDSC1; GDSC2; CTRP2	-8.1985	-6.7619	-8.1985	72.2404
JSC-1	GDSC1; GDSC2	-8.1846	-6.682	-8.1846	69.2772
MV4-11	GDSC1; GDSC2; CTRP2	-8.1217	-7.224	-8.1217	68.3891
NCO2	CTRP2	-8.1134	-2.8992	-8.1319	81.7579
DB	GDSC1; GDSC2; CTRP2	-8.0987	2.6769	-8.7289	65.4989
NB4	GDSC1; GDSC2; CTRP2	-8.0461	-6.8675	-8.0461	75.3775
Kasumi-2	CTRP2	-8.0314	-5.3113	-8.0314	85.5435
MOLP-8	GDSC1; GDSC2; CTRP2	-7.9752	2.3456	-8.5288	65.4106
NALM-6	GDSC1; GDSC2; CTRP2	-7.8232	-6.5573	-7.8232	70.1943
HuNS1	CTRP2	-7.7422	-6.175	-7.7422	84.9805
H9	GDSC1; GDSC2	-7.7046	-5.8372	-7.7046	66.3823
DEL	GDSC1; GDSC2; CTRP2	-7.6862	-6.6854	-7.6862	69.4469
NU-DUL-1	GDSC1; GDSC2; CTRP2; CTRP1	-7.6519	-7.0962	-7.6519	73.1086
BALL-1	GDSC1; GDSC2	-7.5474	-6.5934	-7.5474	65.4429
NKM-1	GDSC1; GDSC2	-7.5414	-6.5373	-7.5414	65.4067
EB2	GDSC1; GDSC2	-7.519	-5.0626	-7.5191	65.2336
HAL-01	GDSC1; GDSC2	-7.4273	-6.1502	-7.4273	64.7195
Farage	GDSC1; GDSC2	-7.3975	-5.4061	-7.3975	68.4964
HEL	GDSC1; GDSC2; CTRP2	-7.3676	-5.8061	-7.3676	71.4676
JURL-MK1	GDSC1; GDSC2; CTRP2	-7.3672	-4.8656	-7.3672	71.3855
KOPN-8	GDSC1; GDSC2	-7.3289	-2.0929	-7.3829	63.1591
IM-9	GDSC1; GDSC2	-7.3131	-6.4321	-7.3131	64.0322
Raji	GDSC1; GDSC2; CTRP2	-7.2876	-6.2381	-7.2876	67.2726
OCI-AML-2	GDSC1; GDSC2; CTRP2	-7.2371	-5.8775	-7.2371	66.997
A3/Kawakami	GDSC1; GDSC2; CTRP2	-7.202	-6.0738	-7.202	66.806
KMS-21-BM	CTRP2	-7.1815	-5.4567	-7.1815	81.3019
SR	GDSC1; GDSC2	-7.1786	-5.159	-7.1787	63.2155
KE-97	CTRP2; CTRP1	-7.1339	-5.5815	-7.1339	81.2547
WIL2 NS	GDSC1; GDSC2	-7.1239	-6.1097	-7.1239	62.8928
MOLM-16	GDSC1; GDSC2; CTRP1	-7.1206	-4.9894	-7.1206	66.7227
L-540	GDSC1; GDSC2; CTRP2	-7.1198	-4.6906	-7.1198	66.3346
OCI-AML-3	GDSC1; GDSC2; CTRP2; CTRP1	-7.0902	-5.6868	-7.0902	66.1954
ARH-77	GDSC1; GDSC2	-7.0553	-5.7485	-7.0553	62.48
KE-37	GDSC1; GDSC2; CTRP2	-7.0544	-5.7555	-7.0544	66.0003
Mino	CTRP2	-7.052	18.0246	-13.0608	59.5937
JVM-3	GDSC1; GDSC2; CTRP2	-7.0515	-6.253	-7.0515	65.9848
Namalwa	GDSC1; GDSC2; CTRP2	-7.0275	-4.6312	-7.0276	65.8349
CESS	GDSC1; GDSC2	-7.0136	-5.1408	-7.0136	62.2255
JVM-2	GDSC1; GDSC2	-6.9157	-4.643	-6.9158	61.6265
RPMI-6666	GDSC1; GDSC2; CTRP2	-6.897	-4.2234	-6.8971	65.1075
BL-41	GDSC1; GDSC2	-6.8812	-6.0421	-6.8812	61.432
SU-DHL-1	GDSC1; GDSC2; CTRP2	-6.8745	-5.2023	-6.8745	79.3189
DoHH2	GDSC1; GDSC2; CTRP2	-6.8677	0.9519	-7.1097	71.8872
MOLT-3	CTRP2	-6.7977	-4.7819	-6.7978	78.7037
ML-2	GDSC1; GDSC2	-6.7941	-5.5613	-6.7941	60.9074
U-937	CTRP1	-6.7897	-4.7156	-6.8007	68.0001
HC-1	GDSC1; GDSC2	-6.7839	-5.6581	-6.7839	60.846
KMS-26	CTRP2	-6.7684	-5.1501	-6.7684	75.367
CRO-AP2	GDSC1; GDSC2	-6.7027	-4.9697	-6.7027	64.0765
SCC-3	GDSC1; GDSC2	-6.7017	-5.802	-6.7017	60.3511
EoL-1	GDSC1; GDSC2; CTRP2	-6.6886	-5.2678	-6.6886	64.0052
A4/Fukuda	GDSC1; GDSC2; CTRP2	-6.6612	-0.8339	-6.7246	62.8864
MHH-CALL-4	GDSC2; CTRP2	-6.6397	-2.2116	-6.6518	75.5239
NK-92MI	GDSC1; GDSC2	-6.6306	-4.4793	-6.6307	86.1964
P32/ISH	GDSC1; GDSC2	-6.6177	-5.3527	-6.6177	59.8451
HEL 92.1.7	CTRP2	-6.5614	-6.0909	-6.5614	77.3194
Karpas-231	GDSC1; GDSC2	-6.5485	-5.6979	-6.5485	59.4284
SIG-M5	GDSC1; GDSC2; CTRP2	-6.5319	-5.1356	-6.5319	77.104
KMS-20	CTRP2	-6.515	4.7838	-7.5005	66.3052
CTV-1	GDSC1; GDSC2	-6.5106	-5.051	-6.5106	59.2005
P12-Ichikawa	GDSC1; GDSC2; CTRP2	-6.4901	-4.9894	-6.4901	62.9223
SET-2	CTRP2	-6.4901	-4.0196	-6.4901	76.5116
MOLT-16	GDSC1; GDSC2; CTRP2	-6.4494	-4.9003	-6.4494	62.7002
SUP-T1	GDSC1; GDSC2; CTRP2	-6.4484	0.3045	-6.5912	61.3685
CML-T1	GDSC1; GDSC2; CTRP2	-6.3949	-4.768	-6.3949	62.4026
ALL-PO	GDSC1; GDSC2	-6.3634	-3.9753	-6.3637	58.3041
WSU-NHL	GDSC1; GDSC2	-6.3603	-4.5406	-6.3603	58.2944
MOLM-13	GDSC1; GDSC2; CTRP2	-6.323	-4.6679	-6.323	62.0104
L-428	GDSC1; GDSC2; CTRP2	-6.2919	-2.9471	-6.2937	61.7625
Ci-1	CTRP2	-6.2344	3.2947	-6.8346	67.0171
BC-1	GDSC1; GDSC2	-6.1982	-4.6206	-6.1982	57.3193
RPMI-8866	GDSC1; GDSC2	-6.1891	-2.6471	-6.1979	70.5017
JeKo-1	GDSC1; GDSC2; CTRP2	-6.1672	-4.9774	-6.1672	64.5592
KMS-27	CTRP2	-6.1535	-4.2363	-6.1535	70.6329
PL21	CTRP2; CTRP1	-6.0453	-3.8973	-6.0453	73.7642
NOMO-1	GDSC1; GDSC2; CTRP2; CTRP1	-6.0367	-4.1285	-6.0367	60.448
GR-ST	GDSC1; GDSC2	-5.9722	-0.0731	-6.1356	55.4313
VL51	GDSC1; GDSC2	-5.8988	-3.3737	-5.8996	55.5081
Ku812	GDSC1; GDSC2; CTRP2; CTRP1	-5.8958	-0.5379	-5.9466	59.5567
RS4;11	GDSC1; GDSC2; CTRP2	-5.8205	-3.492	-5.8206	59.2645
SUP-B8	GDSC1; GDSC2	-5.799	-4.1866	-5.799	58.3029
OCI-M1	GDSC1; GDSC2; CTRP2	-5.7737	-4.4934	-5.7737	59.0143
Jiyoye	GDSC1; GDSC2	-5.7591	-2.237	-5.7701	54.6212
Mono-Mac-6	GDSC1; GDSC2; CTRP2	-5.7545	-2.8456	-5.7553	58.8872
SU-DHL-8	GDSC1; GDSC2; CTRP2	-5.6995	-4.8683	-5.6995	58.6092
SKM-1	GDSC1; GDSC2; CTRP2; CTRP1	-5.672	-3.3394	-5.6721	61.6967
AML-193	CTRP2	-5.657	-0.9011	-5.6877	69.5504
MLMA	GDSC1; GDSC2	-5.6429	-0.8262	-5.7151	53.7974
P30/OHK	GDSC1; GDSC2	-5.5782	-4.4541	-5.5782	53.5868
LAMA-84	GDSC1; GDSC2; CTRP2	-5.5754	-2.8433	-5.5759	57.9201
SU-DHL-4	GDSC1; GDSC2; CTRP2; CTRP1	-5.5245	-1.0965	-5.5457	60.5286
ALL-SIL	GDSC1; GDSC2; CTRP2	-5.5193	-3.915	-5.5193	57.6264
NCI-H929	GDSC1; GDSC2; CTRP2	-5.4836	-2.5583	-5.4872	53.0051
THP-1	GDSC1; GDSC2; CTRP1	-5.4597	-4.4799	-5.4597	56.1344
MHH-CALL-2	GDSC1; GDSC2	-5.4001	-3.3329	-5.4003	52.5134
KYO-1	CTRP2	-5.3628	-2.3385	-5.3643	69.0211
Karpas-1106P	GDSC1; GDSC2	-5.3622	-2.4139	-5.3664	52.2767
ST486	GDSC1; GDSC2; CTRP2	-5.3421	11.1332	-8.3851	53.6236
KO52	CTRP2	-5.3365	-3.078	-5.3366	69.084
MJ	CTRP2	-5.3322	3.234	-5.8419	63.9761
TK [Human B-cell lymphoma]	GDSC1; GDSC2	-5.2852	-3.2444	-5.2854	51.8222
CTB-1	GDSC1; GDSC2	-5.2675	-1.0921	-5.3084	54.7442
RPMI-8402	GDSC1; GDSC2; CTRP2	-5.2672	-3.3908	-5.2672	56.2508
MM1.S	GDSC2	-5.1663	-2.126	-5.1723	51.1013
OCI-Ly19	GDSC1; GDSC2; CTRP2	-5.1637	-1.465	-5.1715	58.6663
PF-382	GDSC1; GDSC2; CTRP2	-5.1116	-3.5008	-5.1116	50.7771
Ri-1	CTRP2	-5.0946	3.5713	-5.6559	62.7763
Reh	GDSC1; GDSC2; CTRP2	-5.0511	-3.0699	-5.0511	55.0718
MOLM-6	CTRP2	-5.0362	2.0528	-5.3081	63.8621
KCL-22	GDSC1; GDSC2; CTRP2	-5.0127	-0.9018	-5.03	54.7882
GA-10	GDSC1; GDSC2; CTRP2	-5.0021	4.8173	-5.8584	53.7049
CCRF-CEM	GDSC1; GDSC2	-4.9595	-2.9318	-4.9597	49.8615
Karpas-299	GDSC1; GDSC2; CTRP2	-4.8911	-1.9403	-4.8927	54.1899
HuT 78	CTRP2	-4.882	-0.9266	-4.8964	65.4875
SUP-B15	GDSC1; GDSC2; CTRP2	-4.8575	-2.5007	-4.8577	54.0145
MY-M12	GDSC1; GDSC2	-4.8432	-2.0606	-4.8472	71.4394
RCH-ACV	GDSC1; GDSC2; CTRP2	-4.8288	-1.6863	-4.8317	56.8173
RPMI-8226	GDSC1; GDSC2; CTRP2; CTRP1	-4.7872	-0.2276	-4.8232	53.5443
Ki-JK	CTRP2	-4.7439	1.4382	-4.9123	63.058
EM-2	GDSC1; GDSC2; CTRP2	-4.7391	-3.4333	-4.7391	53.3701
SUP-M2	GDSC1; GDSC2; CTRP2	-4.7129	-3.2965	-4.7129	53.2275
KY821	GDSC1; GDSC2	-4.7099	-2.8439	-4.7101	48.359
KHM-1B	CTRP2	-4.6185	-0.0135	-4.6598	63.4653
LC4-1	GDSC1; GDSC2	-4.5943	-1.0311	-4.6188	47.6909
OCI-AML-5	GDSC1; GDSC2; CTRP2	-4.5706	-2.4788	-4.5707	55.3642
EJM	GDSC1; GDSC2; CTRP2; CTRP1	-4.4935	4.9643	-5.3428	51.5987
Granta-519	GDSC1; GDSC2; CTRP2	-4.3884	0.0889	-4.4278	51.4252
SU-DHL-6	GDSC1; GDSC2; CTRP2	-4.3558	-0.7903	-4.3657	51.2703
HL-60	GDSC1; GDSC2; CTRP2	-4.2025	-2.8515	-4.2025	50.4429
KG-1	GDSC1; GDSC2	-4.1851	-1.9859	-4.1862	45.2014
BCP-1	CTRP2	-4.1838	4.4692	-4.8755	58.4462
HD-MY-Z	CTRP2	-4.1749	12.7266	-7.806	55.1506
DND-41	GDSC1; GDSC2; CTRP2	-4.1603	-2.3943	-4.1603	50.2127
CMK	GDSC1; CTRP2	-4.1539	-3.2229	-4.1539	52.9665
OCI-Ly7	GDSC1; GDSC2	-4.1048	-2.9933	-4.1048	47.4735
M-07e	CTRP2	-4.1027	4.4945	-4.7935	58.0842
MC116	GDSC1; GDSC2; CTRP1	-4.0858	0.1264	-4.1156	52.958
Sc-1	GDSC1	-4.0328	2.0883	-5.0957	36.5015
Jurkat	GDSC1; GDSC2; CTRP2	-4.0273	-2.5937	-4.0273	49.4873
MEG-01	GDSC1; GDSC2	-4.024	4.4573	-5.0314	45.4405
TALL-1 [Human adult T-ALL]	GDSC2; CTRP2	-4.0021	5.3775	-4.9213	57.21
TUR	GDSC1; GDSC2	-3.9964	-1.9059	-3.9973	44.0652
SUP-HD1	GDSC1; GDSC2; CTRP2	-3.8686	0.6826	-3.9239	48.6545
BV-173	GDSC1; GDSC2	-3.8043	-0.2114	-3.8456	43.0014
P31/FUJ	GDSC1; GDSC2; CTRP2	-3.7074	-1.6611	-3.7076	47.7426
MOLT-4	GDSC1; GDSC2	-3.5318	-2.0435	-3.5319	41.2658
SU-DHL-16	GDSC1; GDSC2	-3.4906	1.6577	-3.7335	44.0025
SU-DHL-10	GDSC1; GDSC2	-3.4469	4.1855	-4.3178	42.3439
BE-13	GDSC1; GDSC2	-3.4311	0.2848	-3.4924	40.8154
AMO1	GDSC1; GDSC2; CTRP1	-3.3249	1.0926	-3.4671	40.3704
Karpas-422	GDSC1; GDSC2; CTRP2	-3.2898	1.8405	-3.4178	45.6431
EHEB	GDSC1; CTRP2	-2.9596	3.0648	-3.2407	46.4084
VAL	GDSC1; GDSC2	-2.9238	3.2728	-3.4809	38.9393
YT	GDSC1; GDSC2	-2.7926	3.0811	-3.2869	38.0571
U-698-M	GDSC1; GDSC2	-2.7387	8.4179	-5.1449	40.9768
L-1236	GDSC1; GDSC2	-2.707	10.1285	-5.8497	41.6923
Daudi	GDSC1; GDSC2; CTRP2	-2.6986	2.6995	-2.9003	42.6215
KM-H2	GDSC1; GDSC2; CTRP2	-2.6499	3.4757	-2.9823	42.5756
Kasumi-1	GDSC1; GDSC2; CTRP2	-2.4905	1.3822	-2.5389	43.4899
MOLT-13	GDSC1; GDSC2; CTRP2	-2.4249	-0.5892	-2.4251	40.7464
OCI-Ly10	CTRP2; CTRP1	-2.3369	9.5682	-4.5775	49.5055
KMOE-2	GDSC1; GDSC2	-2.2108	6.782	-3.9179	37.3898
BC-3	GDSC1; GDSC2	-2.2073	0.1995	-2.2213	48.996
PL-21	GDSC1; GDSC2	-2.1799	1.6587	-2.3236	35.6043
HT	GDSC1; GDSC2; CTRP2; CTRP1	-2.1723	6.8569	-3.3498	43.8004
L-363	GDSC1; GDSC2; CTRP2	-2.1267	3.874	-2.496	39.9125
HPB-ALL	CTRP2	-2.1031	7.404	-3.5073	48.333
GDM-1	GDSC1; GDSC2; CTRP2; CTRP1	-1.9612	4.0573	-2.3559	39.0945
TF-1	CTRP2	-1.9528	4.3408	-2.4118	47.0772
RC-K8	GDSC1; GDSC2	-1.9521	4.513	-2.7981	34.1113
SUP-T11	CTRP2	-1.864	3.2504	-2.0918	46.3319
Peer	CTRP2	-1.6558	6.8781	-2.8395	46.0006
BL-70	CTRP2; CTRP1	-1.5905	5.524	-2.2998	45.7258
CA46	GDSC1; GDSC2; CTRP2	-1.5482	4.2021	-1.9391	36.9094
MHH-PREB-1	GDSC1; GDSC2	-1.5374	6.5622	-3.1176	33.6228
RL	GDSC1; GDSC2; CTRP2	-1.4156	8.7872	-3.2908	40.7001
P3HR-1	CTRP2; CTRP1	-1.34	6.128	-2.2085	44.4991
DG-75	GDSC1; GDSC2	-1.1038	7.0381	-2.8589	31.7323
KMS-12-BM	GDSC1; GDSC2; CTRP2	-1.0857	6.7721	-2.186	36.0387
Loucy	GDSC1; GDSC2	-0.8512	9.9502	-3.8907	33.3992
ME1	CTRP2	-0.6022	6.6186	-1.6097	39.9985
JJN-3	GDSC1; GDSC2; CTRP2	-0.5478	10.2472	-2.9806	36.0216
Ramos.2G6.4C10	GDSC1; GDSC2	-0.513	6.0382	-1.8247	27.2236
Mono-Mac-1	CTRP2	-0.3956	1.9884	-0.41	36.289
MOLP-2	CTRP2	-0.232	10.627	-2.8183	40.5816
MHH-CALL-3	CTRP2	-0.1104	5.4323	-0.6917	36.0551
OPM-2	GDSC1; GDSC2; CTRP2	-0.0181	11.383	-2.9334	34.5575
HDLM-2	GDSC1; GDSC2; CTRP2	0.2617	6.669	-1.2862	23.5286
ME1	GDSC1; GDSC2	0.7177	7.5088	-1.2024	22.1443
SK-MM-2	GDSC1; GDSC2; CTRP2	0.8785	6.2765	0.1105	24.9414
MN-60	GDSC1; GDSC2	1.1378	7.5618	-0.8111	19.8512
KMS-18	CTRP2	1.3633	6.1616	0.6748	26.9162
KMS-11	GDSC1; GDSC2; CTRP2; CTRP1	1.3902	14.7244	-3.0987	32.8333
U266B1	GDSC1; GDSC2; CTRP2	2.1144	10.4721	-0.3782	23.518
F-36P	CTRP2	2.5261	15.2625	-2.29	31.8257
Pfeiffer	CTRP2	2.6167	13.5877	-1.3876	29.5435
ROS-50	GDSC1; GDSC2	2.7929	10.443	-0.6886	16.8941
K-562	GDSC1; GDSC2; CTRP2	3.8993	15.2249	-1.029	21.8018
Karpas-45	GDSC1; GDSC2	5.2441	12.2957	0.3185	8.4009
REC-1	CTRP2	5.4829	16.1493	-0.1469	19.6746
HH [Human lymphoma]	GDSC1; GDSC2	5.6323	7.8335	2.5788	0.5729
LP-1	GDSC1; GDSC2; CTRP2; CTRP1	7.4163	17.9198	0.4605	12.6497
Karpas-620	GDSC1; GDSC2; CTRP2	8.5248	18.6065	0.8986	9.4003

Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Oesophagus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TE15	CTRP2	-0.2912	3.2728	-0.4078	35.9141
TE8	CTRP2	2.3705	16.6397	-3.1087	33.7734
KYSE-510	GDSC1; GDSC2; CTRP2	-8.5955	-8.2383	-8.5955	78.5424
TE-15	GDSC1; GDSC2	-5.3676	-2.0691	-5.3768	55.4823
KYSE-270	GDSC1; GDSC2	-5.0027	-1.0505	-5.0375	50.119
TE-5	GDSC1; GDSC2; CTRP2	-3.831	7.4859	-5.4033	48.8738
TE-8	GDSC1; GDSC2	-2.6842	2.2192	-3.7213	24.6036
OE33	GDSC1; GDSC2; CTRP2	-1.1913	14.2056	-5.393	40.9085
TE-14	CTRP2	-0.8011	7.0828	-1.9884	41.4343
TE-4	GDSC1; GDSC2; CTRP2	-0.7261	3.9976	-1.0013	32.2196
TE-9	GDSC1; GDSC2; CTRP2	0.1532	6.5437	-1.3431	23.9846
EC-GI-10	GDSC1; GDSC2; CTRP2	0.6439	7.5765	-0.6266	27.6104
TE-10	GDSC1; GDSC2; CTRP2	1.3776	19.8794	-6.6282	34.224
TE-6	GDSC1; GDSC2; CTRP2	1.466	11.0908	-1.3076	27.4544
OE21	GDSC1; GDSC2; CTRP2	2.0863	18.4495	-4.2589	32.1702
TE-11	GDSC1; GDSC2; CTRP2	2.6235	9.1814	0.7256	20.1443
COLO 680N	GDSC1; GDSC2; CTRP2	3.7317	13.5709	-0.3568	20.234
KYSE-140	GDSC1; GDSC2; CTRP2; CTRP1	4.1803	15.7708	-0.9516	21.6641
TE-1	GDSC1; GDSC2	4.6944	10.0127	1.0399	6.5391
KYSE-180	GDSC1; GDSC2; CTRP2	5.8758	20.7119	-2.1077	21.2378
T.T	GDSC1; GDSC2	6.2803	22.1922	-3.7755	19.3894
KYSE-150	GDSC1; GDSC2; CTRP2	6.5442	25.4781	-3.9511	24.1847
KYSE-30	CTRP2	6.5902	21.6778	-2.0218	22.9186
OE19	GDSC1; GDSC2; CTRP2	6.6728	9.7086	3.889	2.0221
KYSE-520	GDSC1; GDSC2; CTRP2	7.4998	16.3745	1.2722	9.4498
KYSE-410	GDSC1; GDSC2; CTRP2; CTRP1	8.9793	18.3554	1.45	7.8569
KYSE-70	GDSC1; GDSC2	9.8273	20.4897	-0.6384	6.5433
KYSE-450	GDSC1; GDSC2; CTRP2; CTRP1	11.4224	24.1498	0.2797	8.7783

Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Pancreas Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
N2a-PK1	CTRP2	8.7458	23.6565	-1.3864	17.8869
PSN1	GDSC1; GDSC2; CTRP2	-5.3987	-2.4169	-5.3999	56.9496
KP-4	GDSC1; GDSC2; CTRP2	-4.6801	-2.6769	-4.6802	53.0483
HuP-T4	GDSC1; GDSC2; CTRP1	-3.9062	2.9625	-4.2277	49.3542
Panc 03.27	GDSC1; GDSC2; CTRP2; CTRP1	-3.6945	3.4384	-4.0877	48.3428
CFPAC-1	GDSC1; GDSC2; CTRP2; CTRP1	-3.4317	19.8293	-10.1382	48.6516
MIA PaCa-2	GDSC1; GDSC2; CTRP2	-2.1918	1.6802	-2.2489	39.6136
BxPC-3	GDSC1; GDSC2; CTRP2	-1.1106	7.0828	-2.3221	36.3857
SUIT-2	GDSC1; GDSC2; CTRP2; CTRP1	-0.4994	8.9293	-2.3208	35.1575
KP-1N	GDSC1; GDSC2	0.1988	6.8671	-1.4376	24.173
Panc 10.05	GDSC1; GDSC2; CTRP2; CTRP1	0.3745	10.3969	-2.0269	32.272
MZ-PC-1	GDSC1; GDSC2	0.548	7.4561	-1.348	24.3591
YAPC	GDSC1; GDSC2	0.6596	9.1037	-2.005	24.8084
PL4	GDSC1; GDSC2	0.6606	10.632	-2.7336	26.8736
Capan-1	GDSC1; GDSC2; CTRP2	0.7398	14.1324	-3.4454	33.6467
SU.86.86	GDSC1; GDSC2; CTRP2	0.9061	6.8525	-0.0684	25.3935
DAN-G	GDSC1; GDSC2; CTRP2	1.3885	14.2561	-2.8759	31.1411
SW1990	GDSC1; GDSC2; CTRP2	1.7696	10.8973	-0.917	25.7606
Panc 08.13	GDSC1; GDSC2; CTRP2	2.4145	9.6368	0.3072	20.8498
QGP-1	GDSC1; GDSC2; CTRP2; CTRP1	3.9558	24.3715	-5.4353	31.9554
SNU-213	CTRP2	4.0037	6.9781	3.1156	10.3682
HuP-T3	GDSC1; GDSC2; CTRP2	4.0803	13.6943	-0.1081	18.8724
PANC-1	CTRP2	4.543	20.1419	-2.9262	28.7217
Panc 04.03	GDSC1; GDSC2; CTRP2	5.0003	18.8345	-1.8875	22.0961
PaTu 8988t	GDSC1; GDSC2; CTRP2	5.6755	23.7791	-3.8024	25.1778
SNU-410	CTRP2	5.7124	10.4255	2.8883	7.8432
Panc 02.03	GDSC1; GDSC2; CTRP2	5.855	20.1187	-1.8284	20.5957
AsPC-1	GDSC1; GDSC2; CTRP2	5.8575	15.8809	0.2879	14.7588
Capan-2	GDSC1; GDSC2; CTRP2; CTRP1	5.9613	11.9564	2.4403	8.3192
KP-2	GDSC1; GDSC2; CTRP2	5.9944	12.4094	2.1205	8.6368
PK-45H	CTRP2	6.9616	11.8085	3.0955	5.1393
KP-3	GDSC1; GDSC2; CTRP2; CTRP1	7.0961	16.9983	0.8039	12.0555
Hs 766T	GDSC1; GDSC2; CTRP2	7.2383	17.7737	0.4026	12.4659
HPAF-II	GDSC1; GDSC2; CTRP2	8.4928	28.6426	-4.0186	21.6997
PaTu 8902	GDSC1; GDSC2; CTRP1	9.0691	24.0967	-1.2429	15.2685
PaTu 8988s	CTRP2	10.195	30.2858	-3.584	21.0803
HPAC	GDSC1; GDSC2; CTRP1	12.6833	34.9223	-3.9747	17.3224

Cancer Drug Sensitivity Data Curated from 75 Cell Line(s) in Skin Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SH4	CTRP2	9.7592	36.1882	-6.7941	27.1601
SK-MEL-30	GDSC1; GDSC2	-7.6651	-1.5638	-7.7693	67.5267
A-375	GDSC1; GDSC2; CTRP2; CTRP1	-7.2924	-4.9678	-7.2924	67.2788
IPC-298	GDSC1; GDSC2	-7.0682	13.7561	-11.9184	56.3813
Hs 294T	CTRP2	-6.9293	23.1805	-15.2462	57.8896
A101D	GDSC1; GDSC2; CTRP2	-6.5083	-1.9534	-6.524	62.6427
A-431	GDSC1; GDSC2	-6.3593	-0.5515	-6.4916	60.6293
A-388	GDSC1; GDSC2	-6.1466	0.4557	-6.3934	59.0157
COLO 679	GDSC1; GDSC2	-5.8894	-0.4991	-6.0016	55.0948
IST-MEL1	GDSC1; GDSC2	-5.8664	-0.3284	-5.9947	54.9342
WM793	GDSC1; GDSC2	-5.4033	7.2192	-7.4899	51.567
RPMI-7951	GDSC1; GDSC2; CTRP2	-5.2803	0.6221	-5.393	55.9076
IGR-37	GDSC1; GDSC2; CTRP2	-4.9278	-1.056	-4.94	54.3497
DJM-1	GDSC1; GDSC2	-4.7314	0.5359	-4.8925	51.3701
MZ-MEL-7	GDSC1; GDSC2	-4.4676	5.968	-6.0245	49.8599
M14	GDSC1; GDSC2	-4.3492	2.4	-4.8173	46.6684
WM35	GDSC1; GDSC2	-4.3118	1.0425	-4.5156	46.2238
451Lu	GDSC1; GDSC2	-4.242	1.9929	-4.6116	48.5479
WM266-4	CTRP2	-4.0752	6.7385	-5.4174	56.8749
LOX-IMVI	GDSC1; GDSC2; CTRP2	-3.6025	2.0703	-3.7777	47.3288
WM278	GDSC1; GDSC2	-3.5396	3.4385	-4.1984	42.5299
MZ-MEL-2	GDSC1; GDSC2	-2.5878	5.6455	-3.8836	40.5545
CJM [Human melanoma]	CTRP2	-2.5391	4.7569	-3.155	50.4239
COLO 800	GDSC1; GDSC2; CTRP2	-2.3251	17.2817	-7.9379	46.5899
WM1552C	GDSC1; GDSC2	-2.012	4.9526	-3.0138	34.8316
A2058	GDSC1; GDSC2; CTRP2	-1.7723	6.0342	-2.6869	39.0969
SH-4	GDSC1; GDSC2	-1.756	13.0498	-6.2262	39.4856
UACC-62	GDSC1; GDSC2; CTRP2	-1.3114	3.5067	-1.5407	35.2628
G-mel	GDSC1; GDSC2	-0.9918	8.2423	-3.2625	34.0466
SK-MEL-5	GDSC1; GDSC2; CTRP1	-0.1374	5.9067	-1.3759	26.305
WT2-iPS	GDSC1; GDSC2; CTRP2	-0.1063	4.9292	-0.5457	29.314
Hs 944.T	CTRP2; CTRP1	0.0306	2.8167	-0.0114	34.2635
K029AX	CTRP2	0.8687	10.7312	-1.7418	35.199
GAK	GDSC1; GDSC2	0.9174	8.1426	-1.2999	21.9951
COLO 741	CTRP2; CTRP1	1.0616	7.5861	-0.132	31.1866
WM115	GDSC1; GDSC2; CTRP2	1.3687	8.5692	-0.2753	24.8891
COLO 783	GDSC1; GDSC2	1.5187	4.1425	1.0817	13.0504
Mel Ho	GDSC1; GDSC2; CTRP2	1.5739	12.0962	-1.6706	29.4034
SK-MEL-28	GDSC1; GDSC2; CTRP1	1.6451	6.6959	0.0931	16.4672
Hs 938.T	GDSC1; GDSC2	1.9022	11.3564	-1.9323	22.9848
G-361	GDSC1; GDSC2; CTRP1	1.9313	16.6002	-3.4049	31.4405
UACC-257	GDSC1; GDSC2; CTRP2	2.0709	11.5965	-0.9498	25.1924
VMRC-MELG	GDSC1; GDSC2	2.2342	7.0144	0.506	13.5289
LB373-MEL-D	GDSC1; GDSC2	2.4332	16.2804	-3.912	27.1637
CP50-MEL-B	GDSC1; GDSC2	2.5374	9.5202	-0.453	16.5544
WM88	CTRP2	2.6395	9.0697	0.7932	22.8654
HMV-II	GDSC1; GDSC2	2.6887	18.6389	-4.8704	27.6534
IGR-39	CTRP2	3.033	14.2627	-1.3322	28.3797
SK-MEL-1	GDSC1; GDSC2; CTRP2; CTRP1	3.3793	9.392	0.3346	11.2113
Mel JuSo	GDSC1; GDSC2; CTRP2	3.4877	16.659	-2.1063	25.2537
SK-MEL-31	GDSC1; GDSC2	3.942	16.7438	-2.8795	21.6693
IGR-1	GDSC1; GDSC2; CTRP2	4.1729	16.2093	-1.28	21.9761
CP66-MEL	GDSC1; GDSC2	4.2302	12.357	-0.4628	13.3952
MMAc-SF	GDSC1; GDSC2	4.3586	15.9204	-2.1356	18.7806
LB2518-MEL	GDSC1; GDSC2	4.6384	23.5596	-5.7219	26.9189
COLO 829	GDSC1; GDSC2; CTRP2	4.7826	17.9093	-1.6075	21.7657
SK-MEL-24	GDSC1; GDSC2; CTRP2	5.0667	13.4339	0.8682	14.1714
MeWo	GDSC1; GDSC2; CTRP2	5.3505	19.8521	-2.1059	22.0538
Hs 839.T	CTRP2	6.1285	8.654	4.0432	2.5184
Hs 688(A).T	CTRP2	6.2115	9.3715	3.7591	3.5215
WM983B	CTRP2	6.4156	16.9385	0.1979	16.8472
SK-MEL-2	GDSC1; GDSC2; CTRP2	6.8106	7.961	4.6726	0.0963
Hs 940.T	GDSC1; GDSC2; CTRP2	7.0424	19.5621	-0.624	16.4129
Hs 936.T	CTRP1	7.3566	46.2252	-13.5377	42.1111
Malme-3M	CTRP2	7.3847	19.5898	-0.3821	17.0771
Hs 934.T	CTRP2	7.4489	14.5999	2.0914	8.3639
COLO 792	GDSC1; GDSC2; CTRP2	7.5338	21.7592	-1.3399	16.9499
RVH-421	GDSC1; GDSC2; CTRP2	7.6152	12.8886	3.0014	4.0681
Hs 852.T	CTRP1	7.7571	23.5841	-1.9507	22.8301
CHL-1	GDSC1; GDSC2	7.867	23.8806	-3.4603	16.4882
HMCB	CTRP2	8.6049	26.0357	-2.652	21.237
Hs 895.T	CTRP2	8.7607	17.4367	1.6037	8.4376
SK-MEL-3	GDSC1; GDSC2; CTRP2	10.1151	20.9902	0.7966	8.4373
HT-144	GDSC1; GDSC2; CTRP2	10.5713	24.1062	-0.3682	10.7994
EquiPSC Line K2	GDSC1; GDSC2	0.3462	18.9353	-7.0849	36.91

Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HCE-4	GDSC1; GDSC2	-8.1298	-5.7691	-8.1298	73.0655
KYSE-220	GDSC1; GDSC2	-6.2172	-0.2516	-6.3743	56.747
OACM5.1 C	GDSC1; GDSC2	-3.4855	2.9163	-4.0005	42.0088
ESO-51	GDSC1; GDSC2	-1.7641	6.0837	-3.168	34.424
OACP4 C	GDSC1; GDSC2	-0.813	9.5026	-3.6474	32.7807
ESO-26	GDSC1; GDSC2	-0.7467	6.8126	-2.3915	29.5004
FLO-1	GDSC1; GDSC2	0.3353	10.4889	-2.9772	28.282
TE-12	GDSC1; GDSC2	3.3738	9.3631	0.3445	11.8578
SK-GT-4	GDSC1; GDSC2	4.2162	16.7263	-2.6504	19.6258
KYAE-1	GDSC1; GDSC2	5.7462	7.4178	2.779	0.1855
KYSE-50	GDSC1; GDSC2	6.0635	17.7104	-1.7352	14.1056

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
COLO 684	GDSC1; GDSC2; CTRP2	1.6631	14.1481	-2.5609	29.9052

Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Autonomic Ganglia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CHP-212	GDSC1; GDSC2; CTRP2	-10.6242	9.6484	-13.502	65.7866
IMR-32	CTRP2	-7.8403	-5.4242	-7.8403	84.8495
SK-N-MC-IXC	GDSC1; GDSC2	-7.129	-6.4611	-7.129	66.8052
Kelly	GDSC1; GDSC2; CTRP2	-6.8302	-3.2043	-6.8327	64.6062
SJNB-17	GDSC1; GDSC2	-5.7336	-1.0598	-5.793	57.476
NB69	GDSC1; GDSC2	-5.6991	-0.6105	-5.7915	54.0786
MHH-NB-11	GDSC1; GDSC2; CTRP2	-5.6896	-1.905	-5.6964	70.6135
SiMa	GDSC1; GDSC2; CTRP2	-5.5001	1.3404	-5.7038	56.7482
IMR-5	GDSC1; GDSC2	-5.4657	-4.2335	-5.4657	52.9094
SJNB-10	GDSC1; GDSC2	-4.1997	0.9298	-4.3788	45.5525
KP-N-SI9s	CTRP2	-3.8265	1.6086	-3.9599	58.2265
SJNB-14	GDSC1; GDSC2	-3.5953	-0.317	-3.6239	41.7208
SJNB-13	GDSC1; GDSC2	-3.4967	1.7684	-4.4006	29.9168
KP-N-YS	GDSC1; GDSC2	-3.4734	13.6949	-8.2302	53.5264
CHP-126	GDSC1; GDSC2; CTRP2	-3.1684	2.5367	-3.3793	47.477
SJNB-5	GDSC1; GDSC2	-2.7262	10.7759	-6.1562	43.6527
CHP-134	GDSC2	-2.5999	3.0922	-3.0795	36.9149
NH-12	GDSC1; GDSC2	-2.5081	4.9953	-3.565	37.6713
NB1	GDSC1; GDSC2; CTRP2	-1.1204	4.8065	-1.62	34.8947
GOTO	GDSC1; GDSC2	-1.0809	8.4436	-3.4426	33.058
SK-N-SH	GDSC1; GDSC2; CTRP2	-0.8901	10.083	-3.2668	37.4341
SJNB-12	GDSC1; GDSC2	-0.7248	10.2521	-3.9042	33.0942
KP-N-RT-BM-1	GDSC2	0.0296	13.6566	-4.7929	43.5649
TGW	GDSC1; GDSC2	0.3043	8.8652	-2.2411	26.3556
SK-N-BE(2)-M17	GDSC1; GDSC2	0.3327	9.3704	-2.4499	26.8779
SK-N-BE(2)	CTRP2	0.4019	5.9284	-0.2884	33.1164
KP-N-YN	GDSC1; GDSC2; CTRP2	0.7374	8.2151	-0.7851	27.8098
NB(TU)1	GDSC1; GDSC2	1.2261	11.8688	-2.803	25.7787
GI-ME-N	GDSC1; GDSC2	2.8339	17.4189	-4.1373	25.8219
SK-N-DZ	GDSC1; GDSC2; CTRP2	2.8462	22.0386	-5.3476	32.4221
SK-N-AS	GDSC1; GDSC2; CTRP2	3.1008	17.1932	-2.7171	27.3354
SJNB-7	GDSC1; GDSC2	3.9848	18.9151	-3.9294	23.3109
NH-6	CTRP2	3.9906	7.6108	2.8038	11.6687
SJNB-6	GDSC1; GDSC2	4.2907	8.4107	1.5328	5.6056
LA-N-6	GDSC1; GDSC2	5.2728	17.1447	-2.0386	16.9589
SK-N-FI	GDSC1; GDSC2; CTRP2	7.8841	23.6476	-2.0098	18.1489

Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-1196	CTRP2	-4.2374	17.091	-9.7728	54.3502
SNU-478	CTRP2	-3.3387	3.1639	-3.953	49.2766
SNU-869	CTRP2	-0.4421	12.2363	-3.746	42.3614
HuCC-T1	GDSC1; GDSC2; CTRP2	1.049	11.8591	-2.0773	30.2368
SNU-1079	CTRP2	3.4359	15.2398	-1.4489	27.7275
SNU-308	CTRP2	4.558	12.3333	-0.4003	13.2258
HuH-28	CTRP2	5.1445	12.9206	-0.2651	11.6026

Cancer Drug Sensitivity Data Curated from 90 Cell Line(s) in Breast Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HCC1806	GDSC1; GDSC2; CTRP2	-8.1381	-3.5498	-8.1457	71.0042
DU4475	GDSC1; GDSC2; CTRP2	-5.0458	2.3695	-5.3693	54.411
HCC1599	GDSC1; GDSC2	-5.011	-2.246	-5.0143	53.2529
HCC38	GDSC1; GDSC2; CTRP2	-4.8301	1.624	-5.0271	53.5371
CAL-148	GDSC1; GDSC2; CTRP2	-4.2108	5.027	-5.4203	46.4897
CAL-51	GDSC1; GDSC2; CTRP2	-3.8936	3.378	-4.3107	48.9048
MDA-MB-468	GDSC1; GDSC2; CTRP2	-3.5395	1.6975	-3.6661	46.9603
AU565	GDSC1; GDSC2; CTRP2	-2.5187	4.0907	-2.97	42.0834
MRK-nu-1	GDSC1; GDSC2	-1.5985	3.9518	-2.2323	31.5045
MDA-MB-157	GDSC1; GDSC2; CTRP2	-1.3947	3.7728	-1.6809	35.8492
SK-BR-3	CTRP2	-1.0201	15.3881	-5.7654	45.5569
HMC-1-8	CTRP2	0.3709	19.5337	-6.3871	42.4054
CAL-85-1	GDSC1; GDSC2; CTRP2	0.7891	8.5852	-0.8848	27.9496
MDA-MB-231	GDSC1; GDSC2; CTRP2	0.8651	15.139	-3.8017	33.9652
MDA-MB-436	GDSC1; GDSC2	1.3609	10.4401	-1.9795	23.1344
MCF-7	GDSC1; GDSC2; CTRP2; CTRP1	1.9686	12.462	-1.4605	26.7293
CAL-120	GDSC1; GDSC2	2.3348	12.965	-2.3451	22.1826
HCC1569	GDSC1; GDSC2	2.7573	24.377	-7.6798	33.1274
OCUB-M	GDSC1; GDSC2	2.9868	16.4602	-3.5285	24.1028
MDA-MB-453	GDSC1; GDSC2; CTRP2	3.0385	15.0646	-1.722	25.1903
Evsa-T	GDSC1; GDSC2	3.4511	11.237	-0.5285	14.2144
UACC-812	GDSC1; GDSC2	4.0292	9.0848	1.0066	7.6288
MDA-MB-175-VII	GDSC1; GDSC2	4.1136	22.0589	-5.3953	26.2403
MDA-MB-330	GDSC1; GDSC2	4.8036	8.5077	1.8354	3.7421
EFM-19	GDSC1; GDSC2	4.8343	8.2947	1.9545	3.073
HCC2157	GDSC1; GDSC2	4.9285	14.4396	-0.9614	13.2902
HCC1937	GDSC1; GDSC2; CTRP2	5.0702	7.9217	2.2638	1.8057
BT-549	GDSC1; GDSC2; CTRP2	5.282	14.4614	0.5324	14.892
EFM-192A	GDSC1; GDSC2; CTRP2	5.3752	15.3275	0.1758	15.8432
HCC2218	GDSC1; GDSC2; CTRP2	5.4356	10.7502	2.5106	8.5643
KPL-1	CTRP2	5.4589	7.1992	4.2898	2.4555
BT-483	GDSC1; GDSC2	5.6533	9.8868	1.7186	3.0269
UACC-893	GDSC1; GDSC2	5.7117	13.0058	0.2977	8.3241
HCC1187	GDSC1; GDSC2	5.7602	7.2813	2.8319	0.1213
Hs 578Bst	CTRP2	6.2039	9.1959	3.8371	3.2243
HCC1500	GDSC1; GDSC2; CTRP2	6.2608	14.2809	1.3966	10.6651
HCC1143	GDSC1; GDSC2	6.3562	17.1263	-1.2443	12.1819
HCC202	GDSC1; CTRP2	6.4237	10.8792	3.181	4.784
MFM-223	GDSC1; GDSC2	6.4343	13.2399	0.6544	5.7857
YMB-1-E	GDSC2	6.8966	29.663	-7.0011	30.7654
HCC1428	GDSC1; GDSC2; CTRP2	6.9151	8.3617	4.5691	0.2036
HCC1419	GDSC1; GDSC2; CTRP2	6.953	16.1934	0.9695	11.096
BT-20	GDSC1; GDSC2; CTRP2	7.0293	16.0453	1.0977	10.5922
BT-474	GDSC1; GDSC2; CTRP2	7.211	8.5308	4.6199	0.0877
Hs 578T	GDSC1; GDSC2; CTRP2	7.219	13.6963	2.369	6.2699
COLO 824	GDSC1; GDSC2	7.6286	19.3802	-1.4641	11.2593
HDQ-P1	GDSC1; GDSC2; CTRP2	7.8598	24.4641	-2.4306	19.1688
CAMA-1	GDSC1; GDSC2; CTRP2	8.0666	22.2976	-1.2115	15.9163
T-47D	GDSC1; GDSC2; CTRP2	8.793	21.1952	-0.1608	12.1759
MDA-MB-415	GDSC1; GDSC2	8.8376	19.0758	-0.5715	7.2507
MDA-MB-361	GDSC1; GDSC2; CTRP2	9.0385	27.411	-3.0101	18.9576
HCC1395	GDSC1; GDSC2; CTRP2	9.3387	20.2407	-0.8052	7.4674
HCC1954	GDSC1; GDSC2; CTRP2	9.3833	21.8914	-0.0953	11.3195
HCC70	GDSC1; GDSC2	10.1161	23.5668	-1.8552	9.7031
ZR-75-30	GDSC1; GDSC2; CTRP2	11.3178	25.5058	-0.5506	10.5359
JIMT-1	GDSC1; GDSC2; CTRP2	12.3379	37.0728	-5.3743	19.8385
BT 428	CTRP2	-6.0676	-0.4565	-6.1326	70.9021
BT 145	CTRP2	-5.4866	-3.1821	-5.4867	70.0624
BT164	CTRP2	-5.1445	-1.166	-5.1575	67.1096
BT 112	CTRP2	-3.434	4.9097	-4.1719	54.8945
BT 416	CTRP2	-2.4963	1.0538	-2.5264	50.2328
BT 286	CTRP2	-2.2586	9.642	-4.524	49.1924
BT 239	CTRP2	-1.2125	7.2121	-2.4782	43.7662
BT 245	CTRP2	-0.7799	5.5492	-1.4566	40.4135
BT 330	CTRP2	-0.7332	6.4626	-1.6981	40.677
BT 271	CTRP2	0.4471	5.5302	-0.1134	32.4377
BT 172	CTRP2	1.5099	10.076	-0.7985	31.0254
BT 333	CTRP2	2.5406	11.3653	-0.3857	27.0031
BT 504	CTRP2	2.5819	9.1189	0.7131	23.3026
BT 131	CTRP2	2.8082	10.2155	0.4208	23.7277
BT 340	CTRP2	3.2447	12.2921	-0.1703	24.5723
BT 187	CTRP2	3.3042	14.426	-1.1654	27.3009
BT 248	CTRP2	3.3424	12.3552	-0.111	24.1499
BT 232	CTRP2	3.6489	13.2145	-0.2549	23.8789
BT 440	CTRP2	3.7887	11.4749	0.7309	20.2575
BT 228	CTRP2	4.0496	13.6495	-0.1129	22.5238
BT 139	CTRP2	4.2842	20.2458	-3.1988	29.7765
BT147	CTRP2	5.0087	12.401	1.3363	15.3956
BT 216	CTRP2	5.0131	24.0905	-4.5047	30.7159
BT 498	CTRP2	5.2742	11.9499	1.7812	13.1454
BT 482	CTRP2	5.4581	30.0454	-7.113	33.5547
BT 359	CTRP2	5.6127	11.7376	2.1589	11.0062
BT 231	CTRP2	6.1569	15.9176	0.5048	16.2645
BT 422	CTRP2	6.2216	11.3742	2.7989	7.3791
BT 320	CTRP2	6.2792	7.4	4.6686	0.2893
BT 444	CTRP2	6.4431	24.8155	-3.701	26.8235
BT 179	CTRP2	6.6704	11.252	3.1687	5.2381
BT 159	CTRP2	7.0045	17.5671	0.332	15.4059
BT 328	CTRP2	7.0636	12.305	2.9274	5.6599
BT 224	CTRP2	8.3181	17.4487	1.3125	10.041

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-38	CTRP2	-1.6646	3.8376	-2.3293	38.2725

Cancer Drug Sensitivity Data Curated from 69 Cell Line(s) in Central Nervous System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
D283 Med	GDSC1; GDSC2; CTRP2	-7.1485	-2.4111	-7.1635	65.8917
H4	GDSC1; GDSC2	-6.4546	-3.9279	-6.455	58.8462
MOG-G-UVW	GDSC1; GDSC2	-6.0618	1.4578	-6.4767	55.4297
8-MG-BA	GDSC1; GDSC2; CTRP2	-5.8514	-3.8609	-5.8514	59.4368
D-566MG	GDSC1; GDSC2	-5.7363	-0.3728	-5.8529	57.2629
SF539	GDSC1; GDSC2; CTRP2	-5.3593	-2.2356	-5.3612	56.7293
D-423MG	GDSC1; GDSC2	-5.3248	-3.1052	-5.3252	55.2675
SW1783	GDSC1; GDSC2; CTRP2	-4.8737	2.5041	-5.2068	53.5985
SF126	GDSC1; GDSC2; CTRP2	-4.8478	3.6175	-5.3978	55.623
GI-1	GDSC1; GDSC2	-4.6208	-0.625	-4.6664	47.8675
AM-38	GDSC1; GDSC2	-4.5835	-0.5158	-4.6346	47.6516
Daoy	GDSC1; GDSC2; CTRP2	-4.5598	-1.3288	-4.5641	52.3827
SF268	GDSC1; GDSC2; CTRP2	-4.192	-0.5009	-4.2057	50.3827
42-MG-BA	GDSC1; GDSC2; CTRP2	-3.8798	2.3129	-4.1079	48.7808
D-336MG	GDSC1; GDSC2	-3.7261	7.2261	-5.7016	46.7616
SF295	GDSC1; GDSC2; CTRP2; CTRP1	-3.6357	3.2424	-3.9864	50.4012
M059J	GDSC1; GDSC2	-3.4741	2.7552	-3.948	41.8768
SK-MG-1	GDSC1; GDSC2	-3.3889	8.0411	-5.6705	43.6663
SNU-626	CTRP2	-2.5392	0.1475	-2.5441	50.5205
A-172	GDSC1; GDSC2; CTRP2	-2.1726	6.1886	-3.1715	41.1831
LNZTA3WT4	GDSC1; GDSC2	-1.6541	20.1544	-9.5314	43.221
U-118MG	GDSC1; GDSC2; CTRP2	-1.3452	9.785	-3.6189	39.2487
GB-1	GDSC1; GDSC2; CTRP2	-1.0645	11.3481	-3.9895	38.972
SNU-738	CTRP2	-0.9527	3.344	-1.1268	40.4172
Hs 683	GDSC1; GDSC2; CTRP2	-0.5981	12.1571	-3.8688	39.0515
GOS-3	CTRP2	-0.4694	28.3245	-11.4588	46.3082
Onda 11	GDSC1; GDSC2	-0.1205	16.2816	-6.2108	36.8325
GaMG	GDSC1; GDSC2; CTRP1	-0.073	15.5379	-4.821	37.9417
U-251MG	GDSC1; GDSC2; CTRP2	0.2528	8.8101	-1.5395	30.9382
SNU-489	CTRP2	0.2606	7.3181	-0.9352	35.3537
Becker	GDSC1; GDSC2; CTRP2	0.2891	8.3831	-1.3255	30.3256
Onda 10	GDSC1; GDSC2	0.3658	9.9712	-2.7016	28.8923
KS-1 [Human Krukenberg tumour]	GDSC1; GDSC2	0.909	10.6855	-2.5234	25.7256
LN-18	GDSC1; GDSC2; CTRP2	0.9353	10.9177	-2.611	25.9082
D-392MG	GDSC1; GDSC2	0.9874	8.6879	-1.4896	22.4474
KNS-60	CTRP2	1.0634	4.8564	0.7497	27.5953
D-245MG	GDSC2	1.1494	15.0359	-4.4313	39.5738
MOG-G-CCM	GDSC1; GDSC2	1.3332	11.8895	-2.7143	25.3049
D-247MG	GDSC1; GDSC2	1.4942	16.6213	-4.9063	31.1825
D-502MG	GDSC1; GDSC2	1.6211	7.7079	-0.4109	18.4167
KNS-81-FD	GDSC1; GDSC2	1.8509	10.7403	-1.6747	22.2854
D-263MG	GDSC1; GDSC2	2.0561	12.7267	-2.473	23.1103
SNB-75	GDSC1; GDSC2; CTRP2	2.1945	16.4157	-3.1615	31.1742
PFSK-1	GDSC1; GDSC2	2.2904	18.4279	-5.107	28.8574
SW1088	GDSC1; GDSC2	3.0553	13.913	-2.1974	20.3664
SNU-466	CTRP2	3.1175	6.2994	1.4833	7.4645
ONS-76	GDSC1; GDSC2; CTRP2	3.1241	15.3168	-1.7685	25.1379
KNS-81	CTRP2	3.3385	14.2919	-1.068	26.9602
DBTRG-05MG	GDSC1; GDSC2; CTRP2	4.0521	17.095	-1.8266	23.5657
DK-MG	GDSC1; GDSC2; CTRP2	4.2473	13.6141	0.0784	18.0175
NMC-G1	GDSC1; GDSC2; CTRP2	4.2707	26.1318	-6.1508	32.0797
YH-13	GDSC1; GDSC2; CTRP2	4.3443	17.7586	-1.9051	23.244
M059K	CTRP2	4.3946	16.9765	-1.4714	25.6817
CAS-1	GDSC1; GDSC2; CTRP2	4.5683	18.8019	-2.2351	23.6408
D-542MG	GDSC1; GDSC2	5.3668	18.7656	-2.769	18.9424
KALS-1	GDSC1; GDSC2; CTRP2	5.5213	22.36	-3.2192	24.2508
KINGS-1	GDSC1; GDSC2	5.8137	14.4982	-0.3505	9.9682
T98G	GDSC1; GDSC2; CTRP2	5.9236	19.2849	-1.3571	19.3024
LN-229	GDSC1; GDSC2; CTRP2; CTRP1	5.9241	16.9175	-1.4481	13.4132
U-87MG ATCC	GDSC1; GDSC2; CTRP2	7.1919	28.5603	-4.9753	25.1427
SNU-201	CTRP2	7.3163	23.9807	-2.6035	23.0932
LN-405	GDSC1; GDSC2	7.3947	16.7759	-0.3896	8.1753
KG-1-C	CTRP2	7.4601	12.9998	2.8545	5.4369
SNU-1105	CTRP2	7.5232	14.6755	2.105	8.2097
GMS-10	CTRP2	7.8241	24.0175	-2.237	21.4345
CCF-STTG1	CTRP2	9.2678	19.2156	1.0931	9.5791
YKG-1	GDSC1; GDSC2; CTRP2	9.9932	26.1127	-1.7052	15.4212
KNS-42	GDSC1; GDSC2; CTRP2	10.3886	21.1279	0.8994	7.8646
TM-31	CTRP2	11.0406	37.1063	-6.3056	24.883

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
ETK-1	GDSC1; GDSC2	-2.1101	7.6715	-4.1755	37.545
TGBC24TKB	GDSC1; GDSC2	0.2369	6.6025	-1.2826	23.5788
TGBC1TKB	GDSC1; GDSC2	6.0473	19.4778	-2.6125	16.6873

Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Endometrium Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JHUEM-2	CTRP2; CTRP1	-7.3003	-4.767	-7.3004	81.5169
ESS-1	GDSC1; GDSC2; CTRP2	-5.5606	-3.46	-5.5606	57.85
JHUEM-3	CTRP2	-4.8854	10.223	-7.5434	57.9713
JHUEM-1	CTRP2	-2.0747	13.6641	-6.0433	48.764
HEC-151	CTRP1	-1.2907	4.6923	-4.7342	20.3065
MFE-296	GDSC1; GDSC2; CTRP2	0.0881	6.1562	-0.7044	29.2351
KLE	GDSC1; GDSC2; CTRP2; CTRP1	0.3241	7.3741	-0.8377	29.5882
JHUEM-7	CTRP2	1.4256	16.2939	-3.8218	37.215
HEC-265	CTRP2; CTRP1	1.8424	6.2979	1.1891	24.4734
HEC-6	CTRP2; CTRP1	2.907	9.6734	0.8552	22.7306
RL95-2	GDSC1; GDSC2; CTRP2	3.2456	15.7823	-1.8886	25.1948
MFE-280	GDSC1; GDSC2	5.0169	13.6637	-0.5133	11.6407
HEC-59	CTRP2; CTRP1	6.2273	13.7526	1.7536	12.3399
HEC-251	CTRP2; CTRP1	6.3512	13.6188	1.9143	11.5127
EN	GDSC1; GDSC2; CTRP2	6.6356	8.3865	4.4397	0.5534
AN3-CA	GDSC1; GDSC2; CTRP2	7.9054	16.4896	1.4947	8.2731
HEC-50B	CTRP2	8.1211	15.7036	2.0088	7.7783
HEC-1-A	CTRP2	8.7634	15.9535	2.2891	5.9973
HEC-1-B	CTRP2	8.9405	22.3109	-0.5971	15.3904
MFE-319	GDSC1; GDSC2; CTRP2; CTRP1	9.1742	21.9652	-0.1388	12.2314
HEC-108	CTRP1	10.1942	33.1595	-4.8603	25.1185
Ishikawa (Heraklio) 02 ER-	CTRP2; CTRP1	3.4324	10.2876	1.0711	20.6497

Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Kidney Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
LB2241-RCC	GDSC1; GDSC2	-9.2726	-6.6083	-9.2727	79.9053
BB65-RCC	GDSC1; GDSC2	-8.8421	14.7809	-14.1945	59.5597
KTCTL-140	GDSC1; GDSC2	-7.8193	-4.8961	-7.8199	70.9365
LB1047-RCC	GDSC1; GDSC2	-7.42	0.568	-7.7802	64.4807
HA7-RCC	GDSC1; GDSC2	-7.2817	-2.0375	-7.3372	66.2168
ACHN	GDSC1; GDSC2; CTRP2	-6.8096	-1.7245	-6.837	63.994
SW13	GDSC1; GDSC2	-5.5225	-1.4623	-5.5531	53.1783
SW156	GDSC1; GDSC2	-5.2194	6.5987	-7.0624	52.8546
KTCTL-13	GDSC1; GDSC2	-4.6857	2.8636	-5.2962	50.9659
KTCTL-1M	GDSC1; GDSC2	-4.5218	1.5297	-4.8238	50.1237
BFTC-909	GDSC1; GDSC2; CTRP2	-4.2031	1.1965	-4.3146	50.4255
KTCTL-195	GDSC1; GDSC2	-4.1258	-0.3233	-4.172	44.9294
LB996-RCC	GDSC1; GDSC2	-3.9094	1.2228	-4.1117	43.9097
UO-31	GDSC1; GDSC2; CTRP2	-3.846	6.1431	-4.9789	50.8855
CAL-54	GDSC1; GDSC2; CTRP2	-3.6985	10.296	-6.31	48.5783
786-O	GDSC1; GDSC2; CTRP2	-3.3183	3.0802	-3.6306	45.9847
KTCTL-21	GDSC1; GDSC2	-3.1795	5.2666	-4.3855	43.5364
769-P	GDSC1; GDSC2; CTRP2	-1.7281	68.6287	-32.5542	48.145
KTCTL-26A	GDSC1; GDSC2	-0.6562	10.334	-3.8742	34.3787
TUHR4TKB	CTRP2	-0.6537	13.0469	-4.3256	43.5514
KMRC-3	CTRP2	-0.4257	14.4656	-4.7482	43.2149
NCC010	GDSC1; GDSC2	-0.2206	10.7555	-3.6433	32.709
SN12C	GDSC1; GDSC2	0.0783	4.3568	-0.5462	21.5475
A-704	GDSC1; GDSC2	0.1687	15.5873	-5.6027	34.0421
KMRC-20	GDSC1; GDSC2; CTRP2	0.2537	12.3654	-3.1034	34.1903
NCC021	GDSC1; GDSC2	0.3594	17.4143	-6.3234	35.9115
KMRC-1	GDSC1; GDSC2; CTRP2	0.6071	10.849	-2.0596	31.247
RCC10RGB	GDSC1; GDSC2; CTRP2; CTRP1	2.7279	20.9716	-4.9235	32.0073
TUHR14TKB	CTRP2	3.0756	12.3413	-0.3515	25.5434
RXF 393L	GDSC1; GDSC2	3.9519	22.7569	-5.8757	28.3294
OS-RC-2	GDSC1; GDSC2; CTRP2	4.2103	14.6001	-0.4452	19.6252
SNU-1272	CTRP2	4.6465	8.6584	1.4411	4.892
TUHR10TKB	CTRP2	5.4623	11.6271	2.0945	11.5396
VMRC-RCW	GDSC1; GDSC2; CTRP1	7.2487	12.5655	3.0604	6.542
Caki-1	GDSC1; GDSC2; CTRP2	7.3437	14.0589	2.2794	6.7668
KMRC-2	CTRP2	7.8898	14.1285	2.5978	5.8798
TK-10	GDSC1; GDSC2	8.0321	20.3761	-1.6718	11.403
A-498	GDSC1; GDSC2; CTRP2	8.5213	22.3207	-0.8956	14.5128
Caki-2	CTRP2	10.2452	24.5503	-0.7892	14.2088
VMRC-RCZ	GDSC1; GDSC2; CTRP2	11.142	28.7083	-2.173	14.6886

Cancer Drug Sensitivity Data Curated from 63 Cell Line(s) in Large Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CL-34	CTRP1	-5.9307	-2.6309	-6.1283	55.711
RKO	GDSC1; GDSC2; CTRP2; CTRP1	-5.7561	-3.836	-5.7561	58.9175
SK-CO-1	GDSC1; GDSC2; CTRP2; CTRP1	-5.7216	-2.5208	-5.7233	59.0592
LoVo	GDSC1; GDSC2; CTRP1	-5.3938	-1.7823	-5.4101	52.4445
GP5d	GDSC1; GDSC2	-4.6845	3.5817	-5.4881	48.5617
MDST8	GDSC1; GDSC2; CTRP1	-4.6333	0.0144	-4.7295	47.9789
SW48	GDSC1; GDSC2; CTRP2; CTRP1	-3.7359	0.3659	-3.7666	48.3856
COLO 320HSR	GDSC1; GDSC2	-3.6599	0.7849	-3.7843	42.313
LS180	GDSC1; GDSC2; CTRP2; CTRP1	-3.278	8.14	-5.0383	46.7495
SNU-C5	GDSC1; GDSC2; CTRP1	-3.2651	4.9611	-4.3728	41.7409
HCT 116	GDSC1; GDSC2; CTRP2; CTRP1	-2.8658	7.2526	-4.2783	44.8117
LS513	GDSC1; GDSC2; CTRP2; CTRP1	-2.5981	5.1119	-3.2847	45.3734
NCI-H508	GDSC1; GDSC2; CTRP2; CTRP1	-2.4582	1.6962	-2.5284	43.3471
SW620	GDSC1; GDSC2; CTRP1	-1.7177	6.9467	-3.4641	34.9476
CL-40	CTRP1	-1.4129	2.0644	-3.5242	12.0046
HCC2998	GDSC1; GDSC2	-1.3576	10.6673	-4.7259	36.3215
CaR-1	GDSC1; GDSC2	-0.951	3.1497	-1.2953	26.7958
SNU-175	GDSC2; CTRP2; CTRP1	-0.6996	6.1832	-1.5685	33.5634
CL-11	GDSC1; GDSC2; CTRP2	0.0065	8.598	-1.7107	31.9759
HCT 15	GDSC1; GDSC2; CTRP2	0.3299	11.0766	-2.4428	32.7389
SNU-1040	GDSC1; CTRP1	0.3384	2.588	-2.7068	1.0087
SNU-283	GDSC2	0.3838	7.2777	-1.4325	36.7123
CCK-81	GDSC1; GDSC2; CTRP2	0.4792	9.3459	-1.5299	30.3443
SW480	CTRP1	0.6991	8.9742	-5.3879	17.6578
SW837	GDSC1; GDSC2	0.7027	11.8267	-3.271	28.1575
SW1463	GDSC1; GDSC2; CTRP2	0.7934	7.114	-0.2879	26.2978
LS123	GDSC1; GDSC2; CTRP1	0.8261	9.1102	-1.8465	23.9385
DiFi	GDSC1; GDSC2	0.8398	13.203	-3.8139	29.1266
CW-2	GDSC1; GDSC2; CTRP2; CTRP1	0.8801	7.4639	-0.3314	26.2091
HT115	GDSC1; GDSC2; CTRP2; CTRP1	1.017	7.3607	-0.8364	21.4113
HT-29	GDSC1; GDSC2; CTRP2; CTRP1	1.0913	11.1436	-1.7055	29.2868
SNU-C2B	GDSC1; GDSC2	1.2091	10.3249	-2.0655	23.7285
T84	GDSC1; GDSC2; CTRP2	1.4891	14.0323	-2.6722	30.5127
COLO201	CTRP2	1.5907	8.0375	0.1819	27.8829
LS1034	GDSC1; GDSC2; CTRP2	1.6933	10.0353	-0.5955	25.0538
NCI-H747	GDSC1; GDSC2; CTRP2	1.7693	14.5678	-2.6618	29.8873
KM12	GDSC1; GDSC2; CTRP2; CTRP1	1.8595	9.7437	-0.2957	23.8369
SNU-407	GDSC1; GDSC2	1.9301	10.1949	-1.3337	19.8804
COLO205	GDSC1; GDSC2; CTRP2; CTRP1	2.0811	7.2568	1.0794	19.8882
GP2d	CTRP2; CTRP1	2.0842	6.1682	1.496	22.6664
SNU-C1	GDSC1; GDSC2; CTRP2	2.1164	6.7852	1.249	18.5701
COLO 320	CTRP2; CTRP1	2.1786	7.6365	0.9636	23.5056
SNU-C2A	CTRP2; CTRP1	2.4113	15.7409	-2.5379	33.0972
SW1417	GDSC1; GDSC2; CTRP2	2.6083	8.8321	0.8714	18.6855
DLD-1	CTRP2; CTRP1	2.7143	10.0663	0.4818	24.51
LS411N	GDSC1; GDSC2; CTRP2; CTRP1	2.7914	12.7918	-0.7466	23.7418
SNU-81	GDSC1; GDSC2; CTRP1	3.3213	9.5103	0.2272	12.4129
COLO 678	GDSC1; GDSC2; CTRP2; CTRP1	3.7568	9.2759	1.7787	13.4397
HT-55	GDSC1; GDSC2; CTRP1	3.8552	14.1183	-1.6385	17.2262
SNU-1033	CTRP2	4.0124	13.9545	-0.2974	23.1857
RCM-1 [Human ESC]	GDSC1; GDSC2; CTRP2; CTRP1	4.0936	13.2382	0.1305	18.1321
SNU-61	GDSC1; GDSC2; CTRP1	4.1688	14.6777	-4.2235	11.6545
SNU-503	CTRP2	4.2069	14.6393	-0.4677	23.2785
SW948	GDSC1; GDSC2; CTRP2; CTRP1	4.268	13.1933	0.3061	17.286
SW626	GDSC1; GDSC2	4.2807	19.1232	-3.7946	22.4954
SW1116	GDSC1; GDSC2	4.5309	11.1272	0.3753	9.2054
SNU-C4	CTRP2; CTRP1	5.7143	16.078	0.0755	18.5174
HCT 8	CTRP2; CTRP1	6.2278	8.8686	4.0055	2.5415
OUMS-23	CTRP2	7.0213	7.9663	4.7441	0.0287
HCC-56	CTRP2	8.0244	34.8595	-7.4583	30.2828
NCI-H716	GDSC1; GDSC2; CTRP2	8.5962	17.843	1.3078	8.0849
SW403	CTRP1	9.9961	27.8131	-2.3944	26.7459
C2BBe1	GDSC1; GDSC2; CTRP2; CTRP1	12.6276	35.8942	-4.4776	18.3209

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MO-T	GDSC1; GDSC2	-0.5546	4.3835	-1.2397	25.5124

Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Liver Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HLF	CTRP2	-6.3826	8.0056	-8.3443	63.2341
HLE	GDSC1; GDSC2	-5.1289	0.9386	-5.3763	50.7981
SNU-878	CTRP2	-1.5336	5.4335	-2.2443	44.8941
Li-7	CTRP2	-0.7607	9.3672	-2.8329	42.4378
Hep-G2/C3A	GDSC1; GDSC2	-0.4147	17.0653	-6.8674	37.0941
HuH-1	GDSC1; GDSC2; CTRP2	0.5881	10.2697	-1.8206	30.757
Hep-G2	CTRP1	0.8039	8.6871	-5.1803	16.2911
JHH-5	CTRP2	1.0908	5.7356	0.523	28.2824
JHH-4	GDSC1; GDSC2; CTRP2	2.2035	18.4034	-4.1288	31.7274
SNU-423	GDSC1; GDSC2; CTRP2	3.1267	17.8768	-3.0325	27.9406
SNU-761	CTRP2	4.097	13.1818	0.1615	21.5262
JHH-2	GDSC1; GDSC2; CTRP2	4.2195	13.8441	-0.0605	18.4836
JHH-6	GDSC1; GDSC2; CTRP1	6.2793	8.2844	4.4456	1.3308
Huh-7	GDSC1; GDSC2	6.4219	18.9351	-2.0762	14.6292
JHH-1	GDSC1; GDSC2; CTRP2	6.8317	15.4759	1.2328	10.4212
SNU-475	GDSC1; CTRP2	6.8981	14.6779	1.6715	10.7742
JHH-7	GDSC1; GDSC2	7.0994	19.9978	-2.1165	13.8456
SNU-886	CTRP2	7.293	8.6221	4.6178	0.1037
PLC/PRF/5	CTRP2	7.824	25.6869	-3.0618	23.315
SK-HEP-1	GDSC1; GDSC2; CTRP2	8.2816	18.8239	0.6302	10.4841
Hep 3B2.1-7	GDSC1; GDSC2; CTRP2	8.6965	34.0855	-6.5562	26.4316
SNU-449	GDSC1; GDSC2; CTRP2; CTRP1	9.6759	25.219	-1.3619	14.8503
SNU-398	GDSC1; GDSC2; CTRP2; CTRP1	9.7426	21.2383	0.448	9.4056
SNU-387	GDSC1; GDSC2; CTRP2	10.9523	21.8193	0.9189	6.9375

Cancer Drug Sensitivity Data Curated from 225 Cell Line(s) in Lung Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
DV-90	CTRP2; CTRP1	-10.4927	14.9197	-15.2937	66.3371
SCLC-21H	CTRP1	-8.6075	-3.4654	-8.8643	76.2254
LC-2/ad	GDSC1; GDSC2	-8.5694	-6.1299	-8.5695	75.7754
NCI-H1703	GDSC1; GDSC2; CTRP2	-7.2076	13.1701	-11.1741	57.6469
SBC-5	GDSC1; GDSC2; CTRP2	-7.0807	-3.9914	-7.0812	66.0531
NCI-H290	GDSC1; GDSC2	-6.7715	-3.9886	-6.7723	64.422
NCI-H2170	GDSC1; GDSC2; CTRP2	-6.6804	-3.6603	-6.681	63.9009
NCI-H2110	GDSC1; GDSC2; CTRP2; CTRP1	-6.6693	-3.3585	-6.6706	67.2531
HCC78	GDSC1; GDSC2; CTRP2; CTRP1	-6.422	-0.3222	-6.5048	61.8951
NCI-H847	GDSC1; GDSC2	-6.3959	-3.8359	-6.3965	58.4927
NCI-H1734	GDSC1; GDSC2; CTRP2	-6.2828	-3.2233	-6.2856	71.5744
LB647-SCLC	GDSC1; GDSC2	-5.8276	13.9776	-10.7408	53.4619
NCI-H460	GDSC1; GDSC2; CTRP2; CTRP1	-5.7689	-4.2629	-5.7689	62.2654
NCI-H1876	GDSC1; GDSC2; CTRP1	-5.4604	-3.0642	-5.4611	52.8742
SBC-3	GDSC1; GDSC2	-5.4184	-2.5907	-5.4213	52.6162
ABC-1	GDSC1; GDSC2	-5.2997	-3.5983	-5.2998	55.1116
NCI-H3122	GDSC1; GDSC2	-5.0038	-1.8687	-5.0122	50.1276
NCI-H1623	GDSC1; GDSC2; CTRP2	-4.984	10.5204	-7.764	52.6866
NCI-H1781	GDSC1; GDSC2; CTRP1	-4.9165	-0.6973	-4.9684	49.6131
COLO 668	GDSC1; GDSC2; CTRP2; CTRP1	-4.8871	-2.2359	-4.8877	54.5821
NCI-H1568	GDSC1; GDSC2; CTRP2; CTRP1	-4.8582	2.6814	-5.2051	53.8656
NCI-H292	GDSC1; GDSC2; CTRP2	-4.8421	1.0236	-5.0818	51.9644
EMC-BAC-2	GDSC1; GDSC2	-4.7241	-1.5326	-4.7355	48.4545
COR-L279	GDSC1; GDSC2; CTRP1	-4.5954	-2.2231	-4.5956	53.0082
HCC1438	CTRP2	-4.5623	-2.8484	-4.5623	63.9961
NCI-H1155	GDSC1; GDSC2; CTRP2	-4.5278	-2.7455	-4.5278	52.2175
NCI-H1339	CTRP2	-4.5207	3.0398	-4.9232	60.8201
NCI-H211	GDSC1; GDSC2; CTRP2	-4.504	0.9861	-4.6111	51.9836
NCI-H23	GDSC1; GDSC2; CTRP2; CTRP1	-4.4464	6.2483	-5.6293	51.6302
EBC-1	GDSC1; GDSC2; CTRP1	-4.4074	3.1566	-4.8049	51.7385
NCI-H209	GDSC1; GDSC2	-4.3997	-2.3012	-4.4003	46.4922
NCI-H1048	GDSC1; GDSC2; CTRP1	-4.3574	-0.1699	-4.3824	51.6959
NCI-H520	GDSC1; GDSC2; CTRP2	-4.226	-1.1626	-4.2296	50.5696
NCI-H2810	GDSC1; GDSC2	-4.2144	3.5109	-4.9551	48.531
Lu-134-A	GDSC1; GDSC2	-3.7999	2.3579	-4.2099	46.0469
Lu-139	GDSC1; GDSC2	-3.7833	5.3257	-5.059	46.6284
NCI-H1341	GDSC1; GDSC2; CTRP2	-3.5751	0.5693	-3.6138	47.0669
HCC1359	CTRP1	-3.56	0.6639	-4.7556	31.3205
SK-MES-1	GDSC1; GDSC2; CTRP2	-3.5558	5.6301	-4.5075	47.536
NCI-H1105	GDSC1; GDSC2; CTRP2; CTRP1	-3.4533	3.7608	-3.9131	49.0738
IST-SL2	GDSC1; GDSC2	-3.2319	2.2863	-3.5766	40.2595
NCI-H1694	GDSC1; GDSC2; CTRP2; CTRP1	-3.1425	0.4274	-3.1634	44.7004
NCI-H526	GDSC1; GDSC2; CTRP2	-3.0725	-1.2804	-3.0731	38.502
DMS 273	GDSC1; GDSC2; CTRP2; CTRP1	-3.0567	4.7755	-3.697	45.4361
NCI-H2087	GDSC1; GDSC2; CTRP2	-2.8118	2.5231	-2.9957	43.1916
NCI-H748	GDSC1; GDSC2	-2.788	3.5005	-3.3956	53.1171
RERF-LC-MS	GDSC1; GDSC2; CTRP2	-2.7763	4.5011	-3.3486	45.7129
NCI-H2804	GDSC1; GDSC2	-2.7401	1.4325	-2.8901	39.1611
NCI-H2023	GDSC1; GDSC2; CTRP1	-2.698	3.3476	-3.2548	37.6569
NCI-H2803	GDSC1; GDSC2	-2.6338	4.2447	-3.4513	39.9672
COR-L311	GDSC2	-2.5939	1.0466	-2.6846	35.8793
IST-SL1	GDSC1; GDSC2	-2.581	8.6492	-5.0787	42.1528
DMS 454	CTRP2	-2.5589	6.6876	-7.4424	29.3502
A-549	GDSC1; GDSC2; CTRP2; CTRP1	-2.4761	6.0207	-3.4129	42.9975
NCI-H1944	GDSC1; GDSC2; CTRP2; CTRP1	-2.437	6.4546	-3.5058	42.9705
COR-L303	GDSC2	-2.4215	9.0878	-5.1017	53.3757
Lu-135	GDSC1; GDSC2	-2.3925	4.8052	-3.3743	36.8857
NCI-H2081	GDSC1; GDSC2; CTRP2; CTRP1	-2.3733	4.2215	-2.8418	43.4973
NCI-H1651	GDSC1; GDSC2	-2.3715	0.5833	-2.41	34.3938
COR-L32	GDSC1; GDSC2	-2.3172	4.4735	-3.1813	36.2077
NCI-H1930	CTRP1	-2.2823	1.9382	-2.3585	54.8301
NCI-H1993	GDSC1; GDSC2	-2.2506	4.3373	-3.0643	35.7173
HCC366	GDSC1; GDSC2; CTRP2	-2.2173	10.0542	-4.6467	44.6862
Lu-99	CTRP2; CTRP1	-1.9501	-0.7667	-1.9501	47.1791
NCI-H1975	GDSC1; GDSC2; CTRP1	-1.9201	6.7521	-3.0413	40.6255
NCI-H2228	GDSC1; GDSC2; CTRP2	-1.9004	7.0593	-3.1669	40.2836
HCC1588	CTRP2	-1.86	10.2121	-4.3355	47.6264
SBC-1	GDSC1; GDSC2	-1.8297	12.2422	-5.9226	40.7981
A-427	GDSC1; GDSC2	-1.76	8.0549	-3.9729	37.8596
DMS 53	GDSC1; GDSC2; CTRP2	-1.7116	5.7741	-2.5401	38.64
NCI-H2122	GDSC1; GDSC2; CTRP2; CTRP1	-1.6864	17.8839	-7.586	43.7414
NCI-H1304	GDSC1	-1.6459	3.6819	-3.3269	21.3172
NCI-H510A	GDSC1; GDSC2; CTRP2	-1.5071	58.7367	-27.4395	49.1359
NCI-H2286	CTRP2; CTRP1	-1.4958	5.702	-2.2484	45.2392
CPC-N	GDSC1; GDSC2	-1.4681	8.1332	-3.7045	34.7213
Ms-1	GDSC1; GDSC2	-1.4452	3.9035	-2.0502	30.5238
RERF-LC-A1	CTRP2	-1.4047	20.9049	-8.7412	47.514
NCI-H82	GDSC1; GDSC2; CTRP1	-1.3307	11.3359	-4.1936	40.3594
HARA [Human squamous cell lung carcinoma]	GDSC1; GDSC2; CTRP2; CTRP1	-1.0214	8.5353	-2.7189	37.3589
PC-14	GDSC1; GDSC2; CTRP2	-0.9352	7.4416	-2.2633	35.7567
NCI-H146	GDSC1; GDSC2	-0.9235	6.2473	-2.3424	31.5367
NCI-H1792	GDSC1; GDSC2; CTRP2; CTRP1	-0.8855	18.8849	-7.1936	42.0001
HCC15	GDSC1; GDSC2; CTRP2; CTRP1	-0.7699	6.2461	-1.6656	33.9894
PaCa-3	GDSC1; GDSC2	-0.7355	13.1014	-5.2562	35.5864
NCI-H810	GDSC1; GDSC2; CTRP2; CTRP1	-0.6745	18.1594	-6.6447	41.1269
LXF 289	GDSC1; GDSC2; CTRP1	-0.6533	10.8694	-3.2918	37.2763
NCI-H1373	CTRP2; CTRP1	-0.6389	6.177	-1.4613	40.4408
LCLC-97TM1	GDSC1; GDSC2; CTRP2; CTRP1	-0.6386	7.7513	-2.0107	34.9192
NCI-H1395	CTRP2	-0.5975	12.8898	-4.1978	43.2704
NCI-H2373	GDSC1; GDSC2	-0.5627	7.8943	-2.6701	29.7562
EMC-BAC-1	GDSC1; GDSC2	-0.515	4.6796	-1.3014	27.1463
DMS 79	GDSC1; GDSC2	-0.4483	4.5629	-1.1877	26.5747
SW1271	GDSC1; GDSC2; CTRP2	-0.4154	10.7761	-3.0721	35.829
NCI-H69	GDSC1; GDSC2; CTRP2	-0.3972	4.1615	-0.9937	24.2918
EPLC-272H	GDSC1; GDSC2; CTRP2; CTRP1	-0.2701	9.341	-2.2473	34.3922
HOP-62	GDSC1; GDSC2; CTRP2	-0.2626	8.3396	-1.8906	33.0958
Lu-99A	GDSC1; GDSC2	-0.2622	5.0483	-1.1668	24.4898
HCC1833	CTRP1	-0.2135	11.717	-7.3909	28.226
NCI-H446	GDSC1; GDSC2; CTRP2	-0.2015	9.7903	-2.4261	34.0616
HCC44	GDSC1; GDSC2; CTRP2; CTRP1	-0.1981	9.8116	-2.3684	34.4404
NCI-H647	GDSC1; GDSC2; CTRP2	-0.1834	33.8588	-13.922	44.5867
MOR/CPR	CTRP2	-0.0687	23.0368	-8.5018	44.5637
NCI-H838	GDSC1; GDSC2; CTRP2	-0.0422	8.0773	-1.5527	33.3269
NCI-H1437	GDSC1; GDSC2; CTRP1	-0.0222	23.8836	-8.7798	42.3495
COR-L95	GDSC1; GDSC2; CTRP2	0.1661	7.9312	-1.2739	32.0702
NCI-H2171	GDSC1; GDSC2; CTRP2	0.2112	25.1675	-9.2828	44.3474
COR-L51	CTRP2; CTRP1	0.2347	15.1898	-4.4373	41.0814
NCI-H1963	GDSC1; GDSC2; CTRP1	0.336	9.8422	-4.6206	20.0344
Sq-1	CTRP1	0.3364	7.2981	-4.8301	15.6008
NCI-H2795	GDSC1; GDSC2	0.3775	8.4055	-1.9549	25.335
NCI-H2141	GDSC1; GDSC2; CTRP2; CTRP1	0.4876	7.3717	-0.7132	28.2359
NCI-H2405	GDSC1; GDSC2; CTRP2; CTRP1	0.4954	10.3162	-1.8674	31.626
LC-1/sq	GDSC1; GDSC2	0.6238	12.2493	-3.5504	29.0091
NCI-H524	GDSC1; GDSC2	0.665	7.6844	-1.3358	22.7059
NCI-H1435	GDSC1; GDSC2; CTRP1	0.7389	7.9891	-0.634	28.0119
NCI-H2009	GDSC1; GDSC2; CTRP2; CTRP1	0.7432	10.9265	-1.8847	31.0587
Calu-3	GDSC1; GDSC2; CTRP2; CTRP1	0.775	12.0917	-2.381	32.034
LK-2	GDSC1; GDSC2	0.8508	8.6898	-1.6231	23.1873
SW1573	GDSC1; GDSC2	0.8685	8.6993	-1.6103	23.1056
NCI-H1793	GDSC1; GDSC2; CTRP2; CTRP1	1.0949	8.6924	-0.5485	26.9208
COR-L23	GDSC1; GDSC2; CTRP1	1.1068	13.8431	-3.8822	28.6945
NCI-H2227	GDSC1; GDSC2	1.1338	6.0574	-0.1244	18.5307
NCI-H2461	GDSC1; GDSC2	1.1599	13.2681	-3.5507	27.8129
HCC2279	CTRP2	1.1659	8.9342	-0.6424	31.635
NCI-H322M	GDSC1; GDSC2	1.1822	10.365	-2.1103	23.9215
NCI-H2029	GDSC1; GDSC2; CTRP2; CTRP1	1.2096	11.1091	-1.4962	30.4296
SK-LU-1	GDSC1; GDSC2; CTRP1	1.2154	6.1084	-0.0645	17.0624
NCI-H1755	GDSC1; GDSC2; CTRP1	1.2597	13.3902	-3.5195	27.5224
NCI-H250	GDSC2	1.2982	16.3645	-4.9542	39.8023
NCI-H740	GDSC2	1.5678	17.622	-5.3378	39.5149
NCI-H226	GDSC1; GDSC2; CTRP2	1.5755	6.4697	0.7923	21.231
NCI-H1650	GDSC1; GDSC2; CTRP2	1.5871	7.7293	0.3073	22.6724
NCI-H187	GDSC1	1.6369	6.7149	-2.0833	7.5376
NCI-H650	GDSC1; GDSC2; CTRP2; CTRP1	1.679	17.0614	-3.8658	32.7504
NCI-H1581	GDSC1; GDSC2; CTRP2	1.7957	11.3885	-1.1206	26.2401
NCI-H2196	GDSC1; GDSC2; CTRP2	1.833	11.8379	-1.2957	31.3809
NCI-H1666	GDSC1; GDSC2; CTRP2; CTRP1	1.9908	12.5709	-1.4067	27.1052
DMS 114	GDSC1; GDSC2; CTRP2	2.072	10.3539	-0.3651	23.5719
COR-L105	GDSC1; GDSC2; CTRP2	2.2539	14.7778	-2.3067	28.1152
NCI-H1299	GDSC1; GDSC2; CTRP2; CTRP1	2.4208	14.1554	-1.7571	27.0395
NCI-H2073	CTRP1	2.4572	10.9217	-5.1839	12.4587
RERF-LC-Sq1	GDSC1; GDSC2	2.5282	12.7079	-2.0479	20.923
NCI-H2818	GDSC1; GDSC2	2.5606	9.0445	-0.1962	14.6724
NCI-H2722	GDSC1; GDSC2	3.0337	10.8307	-0.6753	15.4808
LC-1/sq-SF	CTRP2; CTRP1	3.0559	10.2444	0.7306	22.7874
KNS-62	GDSC1; GDSC2; CTRP2; CTRP1	3.1943	13.3526	-0.6432	22.6643
LOU-NH91	GDSC1; GDSC2; CTRP2	3.2067	10.7009	0.5692	18.4292
Lu-165	GDSC1; GDSC2	3.2991	11.3623	-0.7173	15.1447
RERF-LC-Ad1	CTRP2	3.3215	5.4238	2.0834	4.1352
NCI-H3255	GDSC1; GDSC2; CTRP1	3.3567	16.6423	-3.3093	23.8919
NCI-H1092	GDSC1; GDSC2; CTRP2	3.4333	10.7652	0.751	17.4163
COR-L321	GDSC1; GDSC2	3.4603	12.4077	-1.1062	17.0698
NCI-H2085	GDSC1; GDSC2	3.5317	12.7521	-1.2195	16.4343
NCI-H441	GDSC1; GDSC2; CTRP2; CTRP1	3.5479	17.5356	-2.4883	26.009
Lu-65	GDSC1; GDSC2; CTRP2; CTRP1	3.6877	15.3346	-1.1712	23.1299
NCI-H345	GDSC1; GDSC2	3.7315	6.6437	1.9888	4.6641
NCI-H2731	GDSC1; GDSC2	3.753	9.3729	0.6478	9.4114
NCI-H358	GDSC1; GDSC2; CTRP2; CTRP1	3.9885	18.8791	-2.6678	26.0887
NCI-H1436	GDSC1; GDSC2	4.1012	7.1442	2.0148	3.9916
NCI-H1385	CTRP2	4.1507	10.1263	1.725	15.6786
UMC-11	GDSC1; GDSC2	4.3432	10.1936	0.6956	8.3095
HCC1195	CTRP2; CTRP1	4.5057	10.0844	2.0625	13.5573
NCI-H2126	CTRP1	4.6083	11.3123	1.6437	29.6679
NCI-H2066	GDSC1; GDSC2	4.6169	7.2921	2.2841	2.1739
HOP-92	GDSC1; GDSC2; CTRP2	4.6626	15.7001	-0.6049	19.2971
NCI-H1838	GDSC1; GDSC2; CTRP2	4.664	10.8193	0.6244	8.1025
NCI-H2135	GDSC1; GDSC2	4.6776	6.9924	2.4554	1.6421
NCI-H1648	GDSC1; GDSC2	4.6813	14.2815	-1.0703	14.032
NCI-H2291	GDSC1; GDSC2; CTRP2	4.7516	11.9935	0.1123	10.4076
NCI-H2869	GDSC1; GDSC2	4.8009	25.7615	-6.6904	28.3514
HCC33	GDSC1; GDSC2; CTRP1	4.8605	30.6782	-7.8168	37.3377
NCI-H522	GDSC1; GDSC2; CTRP2; CTRP1	4.9153	27.9821	-6.4229	30.9117
LK2	CTRP2	4.9461	20.5644	-2.7977	27.6715
NCI-H1573	GDSC1; GDSC2; CTRP2; CTRP1	4.9737	10.6158	2.3074	10.2632
COR-L88	GDSC1; GDSC2; CTRP1	5.0122	17.2694	-0.9857	20.3294
NCI-H1693	GDSC1; GDSC2; CTRP2	5.0522	19.8925	-2.3731	23.156
NCI-H64	GDSC1; GDSC2	5.2076	18.903	-2.9583	18.8809
NCI-H889	CTRP2	5.3146	17.1995	-0.8095	22.013
LCLC-103H	GDSC1; GDSC2; CTRP2; CTRP1	5.3185	17.8925	-1.0414	19.9766
NCI-H2347	GDSC1; GDSC2	5.3577	15.3722	-1.1023	13.1162
NCI-H1836	GDSC1; GDSC2; CTRP1	5.3799	13.8886	-0.36	11.1898
NCI-H720	GDSC1; GDSC2	5.5195	11.836	0.7276	6.5916
T3M-10	CTRP2; CTRP1	5.5267	15.711	0.1075	18.7664
NCI-H2591	GDSC1; GDSC2	5.5389	18.4633	-2.4899	17.0849
NCI-H2444	GDSC1; GDSC2; CTRP2	5.5707	7.0558	4.4362	1.4703
NCI-H1770	GDSC1; GDSC2	5.5914	14.3761	-0.447	11.189
NCI-H727	GDSC1; GDSC2; CTRP2; CTRP1	5.6213	18.911	-1.3012	20.1673
HCC4006	CTRP2; CTRP1	5.6233	7.1712	4.4161	1.7103
SHP-77	GDSC1; GDSC2; CTRP2; CTRP1	5.8725	22.0548	-2.6672	22.9989
NCI-H513	GDSC1; GDSC2	5.9709	17.1372	-1.5218	13.5778
IA-LM	GDSC1; GDSC2; CTRP2	6.0178	9.8348	3.4039	4.2808
COLO 699	CTRP2; CTRP1	6.0582	26.5118	-4.8566	29.4992
NCI-H2595	GDSC1; GDSC2	6.0753	18.8633	-2.2907	15.7356
HCC827	GDSC1; GDSC2; CTRP2; CTRP1	6.0763	16.6397	0.0826	15.0518
VMRC-LCD	GDSC1; GDSC2; CTRP2; CTRP1	6.1964	14.847	1.1864	12.1025
NCI-H661	GDSC1; GDSC2; CTRP2; CTRP1	6.2057	20.435	-1.5898	19.9944
HCC2108	CTRP2; CTRP1	6.2775	16.6621	0.2284	16.988
NCI-H1688	GDSC1; GDSC2	6.6051	17.0698	-1.0457	11.2266
LUDLU-1	CTRP2	6.6232	27.4436	-4.8682	28.609
NCI-H2369	GDSC1; GDSC2	6.6374	19.9256	-2.4053	15.2834
NCI-H196	GDSC1; GDSC2; CTRP2	6.7608	15.3564	-0.1276	8.0396
NCI-H596	GDSC1; GDSC2; CTRP1	6.8444	21.2885	-2.9218	16.425
CAL-12T	GDSC1; GDSC2; CTRP2; CTRP1	7.1739	22.9438	-2.1985	20.3228
NCI-H2106	CTRP2	7.2262	14.9367	1.7774	9.8754
NCI-H841	GDSC1; GDSC2; CTRP2; CTRP1	7.7249	24.5655	-2.5822	19.6933
RERF-LC-Ad2	CTRP2	7.7586	16.8813	1.2068	11.1992
HCC95	CTRP2	7.7761	16.8359	1.2407	11.0524
NCI-H1355	GDSC1; GDSC2; CTRP2; CTRP1	7.7829	26.0662	-3.1595	21.3209
NCI-H2030	GDSC1; GDSC2; CTRP2; CTRP1	7.9302	19.8229	-0.0997	13.6589
HCC1171	CTRP2	8.0036	18.293	0.6947	12.6345
HCC2935	CTRP2; CTRP1	8.0984	20.6427	-0.3793	15.9613
NCI-H2342	GDSC1; GDSC2; CTRP2; CTRP1	8.1679	22.0475	-1.0155	15.2733
NCI-H835	GDSC1; GDSC2	8.313	20.3995	-1.5021	10.5824
EKVX	GDSC1; GDSC2; CTRP2	8.3574	16.1114	1.968	6.6498
NCI-H1869	GDSC1; GDSC2; CTRP2	8.5847	21.1637	-0.2895	12.7833
RERF-LC-KJ	GDSC1; GDSC2; CTRP1	8.7848	24.059	-1.4273	16.0765
NCI-H1563	GDSC1; GDSC2; CTRP2	8.9438	18.9281	1.0211	8.5757
Calu-6	GDSC1; GDSC2; CTRP1	9.6491	30.3462	-3.8783	20.4228
NCI-H322	CTRP2	10.1184	25.0523	-1.1123	15.2692
Calu-1	CTRP2	10.4417	26.5063	-1.5902	16.1291
NCI-H2172	GDSC1; GDSC2; CTRP2; CTRP1	11.0683	23.023	0.441	8.5237
NCI-H1915	GDSC1; GDSC2; CTRP2; CTRP1	11.477	24.6793	0.0695	9.2832
BEN	GDSC1; GDSC2; CTRP2; CTRP1	12.8218	32.2743	-2.6266	14.9555
ChaGo-K-1	GDSC1; GDSC2; CTRP2; CTRP1	15.5822	35.6335	-2.474	12.0964
Hs 888.Lu	CTRP2	8.0336	30.5868	-5.3292	27.244

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CBTCi002-A	GDSC1; GDSC2	1.8212	7.2504	0.0002	15.473

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
H-STS	CTRP2	-6.2632	-5.7633	-6.2632	75.333
P-STS	CTRP2	-6.1394	0.932	-6.3327	69.4616
SYO-1	CTRP2	-4.6978	-1.4157	-4.7022	64.6302

Cancer Drug Sensitivity Data Curated from 48 Cell Line(s) in Ovary Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
2004	CTRP2	-5.2015	6.3041	-6.5051	61.0687
Caov-3	GDSC1; GDSC2; CTRP1	-9.6724	-0.9948	-9.9561	81.6934
HEY A8	CTRP1	-8.6429	5.1886	-9.9024	83.3467
DOV13	GDSC1; GDSC2; CTRP2	-6.9954	-4.8944	-6.9954	65.6714
OVCAR-8	GDSC1; GDSC2; CTRP2; CTRP1	-6.5227	-4.2005	-6.5228	63.0909
OVK18	GDSC1; GDSC2; CTRP1	-6.4836	1.4433	-6.9309	59.9831
TOV-112D	GDSC1; GDSC2; CTRP2	-6.4198	-3.7954	-6.42	62.5186
A2780	GDSC1; GDSC2; CTRP2; CTRP1	-6.3042	-3.5034	-6.3046	61.8802
OC 314	GDSC1; GDSC2; CTRP2	-5.7982	-4.1736	-5.7982	59.1477
JHOC-5	CTRP2; CTRP1	-4.994	2.0971	-5.2696	63.6407
TYK-nu	GDSC1; GDSC2; CTRP1	-4.5684	3.8772	-5.4469	48.023
ES-2	GDSC1; GDSC2	-4.4234	3.2638	-5.1149	47.209
OAW42	GDSC1; GDSC2; CTRP2; CTRP1	-3.9923	0.4943	-4.0406	49.3122
COV434	CTRP2; CTRP1	-2.9188	4.2926	-3.4529	52.4875
MCAS	CTRP2	-1.4213	5.6082	-2.1735	44.3018
SNU-840	CTRP1	-1.1409	4.0204	-4.2858	16.8256
OV7	CTRP2; CTRP1	-0.7954	6.2352	-1.6896	40.9112
OV56	GDSC1; GDSC2; CTRP2	-0.6338	4.8373	-1.0971	32.2137
OVTOKO	GDSC1; GDSC2; CTRP2	0.1228	7.5839	-1.1841	30.3999
RMUG-S	CTRP1	0.1724	6.8048	-4.7046	15.318
IGROV-1	GDSC1; GDSC2; CTRP2; CTRP1	1.2287	20.8723	-6.2378	36.5376
OVCAR-3	GDSC1; GDSC2	1.6497	17.7225	-5.3154	30.4752
Caov-4	GDSC1; GDSC2	1.8414	18.2569	-5.4126	30.2794
OV-90	GDSC1; GDSC2; CTRP2; CTRP1	2.0843	18.1047	-4.0914	31.8981
SNU-8	CTRP2	2.6498	9.6353	0.5402	23.7286
JHOS-2	GDSC1; GDSC2; CTRP2	2.7145	11.2486	-0.1631	22.7408
SK-OV-3	GDSC1; GDSC2; CTRP1	3.2376	16.0316	-1.9215	25.8089
ES2	CTRP2	3.9744	42.8834	-14.774	41.1417
ONCO-DG-1	CTRP2	4.355	18.6624	-2.3473	27.8647
EFO-21	GDSC1; GDSC2; CTRP2; CTRP1	4.6876	25.497	-5.3724	29.7704
COV362	CTRP2; CTRP1	5.8642	16.7893	-0.1596	18.9977
OVKATE	GDSC1; GDSC2; CTRP1	5.9177	7.7767	2.716	0.2316
COV644	CTRP2; CTRP1	5.9759	16.3575	0.1442	17.8082
SNU-119	CTRP2	5.9957	10.718	2.9561	7.0953
EFO-27	GDSC1; GDSC2; CTRP2; CTRP1	6.1129	19.7923	-1.4591	20.095
FU-OV-1	GDSC1; GDSC2; CTRP2	6.1175	9.5819	3.5956	3.5238
OAW28	GDSC1; GDSC2; CTRP2	6.1477	22.371	-2.7175	22.2243
RMG-I	GDSC1; GDSC2; CTRP1	6.6352	16.5707	-0.7862	10.3542
TOV-21G	GDSC1; GDSC2; CTRP2	6.84	24.4057	-3.1835	22.2228
OVMANA	CTRP1	7.2404	10.4306	4.034	2.3572
JHOM-1	CTRP2; CTRP1	7.3683	8.8158	4.5782	0.1271
OVCAR-5	GDSC1; GDSC2; CTRP2	7.4263	26.6169	-3.8268	22.7185
OVSAHO	CTRP2	8.7547	18.9818	0.8723	10.9846
JHOS-4	GDSC1; GDSC2; CTRP1	9.0772	34.1637	-6.1842	25.7421
Kuramochi	GDSC1; GDSC2; CTRP2	10.1645	19.8178	1.3626	6.3895
COV318	CTRP1	10.7088	19.028	2.1661	5.6782
OVISE	GDSC1; GDSC2; CTRP2	10.972	31.3268	-3.5449	17.8481
OVCAR-4	GDSC1; GDSC2; CTRP2; CTRP1	12.355	34.7364	-4.2396	17.7683

Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Soft Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Aska-SS	CTRP2	0.6929	4.6181	0.4048	29.9581
Yamato-SS	CTRP2	3.1974	8.1999	1.7498	17.8343
TE 617.T	CTRP2	-10.5969	0.2117	-10.99	80.6546
G-402	GDSC1; GDSC2; CTRP2	-8.7211	13.91	-13.0712	60.3402
EW-8	GDSC1; GDSC2	-7.4354	-6.2591	-7.4354	64.7684
KYM-1	GDSC1; GDSC2; CTRP2	-7.1349	-6.3343	-7.1349	66.4398
VA-ES-BJ	GDSC1; GDSC2	-6.8804	-2.0074	-6.9246	60.8374
TTC-709	CTRP2	-6.6914	5.4494	-7.8761	66.1414
Hs 633.T	GDSC1; GDSC2	-6.6696	-3.212	-6.6751	60.0338
SK-UT-1	GDSC1; GDSC2; CTRP2	-6.1518	-3.5296	-6.152	61.0606
SK-LMS-1	GDSC1; GDSC2; CTRP2	-4.6438	7.5401	-6.3019	51.9333
MFH-ino	GDSC1; GDSC2	-4.4712	1.4544	-4.7555	47.1936
SW982	GDSC1; GDSC2; CTRP2	-4.3546	0.6443	-4.4265	51.2281
SW872	GDSC1; GDSC2	-4.261	-0.8829	-4.283	45.6962
G-401	GDSC1; GDSC2; CTRP2; CTRP1	-3.9455	3.0746	-4.2902	49.5487
A-204	GDSC1; GDSC2; CTRP2	-3.8723	1.7588	-4.0256	48.7157
TE 441.T	GDSC1; GDSC2; CTRP2	-2.8032	10.469	-5.433	51.2594
Rh30	GDSC1; GDSC2	-2.7996	8.2892	-5.1546	41.1824
Tm87-16	CTRP2	-1.8257	9.3764	-3.9596	47.3506
GCT	GDSC1; GDSC2; CTRP2	-1.7954	4.1597	-2.1984	38.2404
Rh41	GDSC1; GDSC2; CTRP2	-1.3029	9.8401	-3.5972	39.0963
STS-0421	GDSC1; GDSC2	-0.9028	4.9896	-1.8316	29.989
Hs 729.T	CTRP2	-0.6971	10.2372	-3.1313	42.5553
BT-16	CTRP2	0.1143	10.8873	-2.578	39.0954
HT-1080	GDSC1; GDSC2; CTRP2; CTRP1	1.1068	12.5702	-2.3513	30.6991
RKN	GDSC1; GDSC2; CTRP1	1.3465	8.4689	-1.0389	20.1548
MES-SA	GDSC1; GDSC2; CTRP2	3.0134	21.6822	-5.0223	31.6472
SW684	GDSC1; GDSC2	4.3713	8.5439	1.5254	5.1961
BT-12	CTRP2	4.5863	14.0413	0.1587	20.4797
RD	GDSC1; GDSC2; CTRP2	5.9865	22.2137	-2.7684	22.5783
Rh18	GDSC1; CTRP2	7.9923	16.6136	1.4937	8.6042

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
U-CH1	CTRP2	8.1209	24.8748	-2.4382	21.4589

Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Pleura Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MSTO-211H	GDSC1; GDSC2; CTRP1	-3.387	2.5379	-3.6008	46.6996
NCI-H28	GDSC1; GDSC2; CTRP2; CTRP1	-1.0396	8.6191	-2.7708	37.5008
NCI-H2052	GDSC1; GDSC2; CTRP2; CTRP1	1.1036	8.0971	-0.2925	26.1965
NCI-H2452	GDSC1; GDSC2; CTRP2	1.9937	6.7934	1.1154	19.266
MPP 89	GDSC1; GDSC2; CTRP2	2.9408	16.4857	-2.5117	27.1992
IST-Mes1	GDSC1; GDSC2; CTRP2	3.4121	15.6475	-1.6722	24.3555
ACC-MESO-1	CTRP2	6.2368	8.3342	4.2548	1.6033
JL-1	CTRP2	7.0573	10.2831	3.8513	2.2124

Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Prostate Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
22Rv1	GDSC1; GDSC2; CTRP2	-3.8393	0.9268	-3.9104	48.5065
DU145	GDSC1; GDSC2; CTRP2	-0.9336	10.0545	-3.3002	37.608
LNCaP clone FGC	GDSC1; GDSC2; CTRP2	0.0352	10.2081	-2.3609	33.3148
VCaP	GDSC1; GDSC2; CTRP2	1.4943	17.3368	-4.2636	33.3638
PC-3	GDSC1; GDSC2	3.49	14.5667	-2.161	19.4675
PaCa-3	CTRP2; CTRP1	3.6437	8.9918	1.8951	17.0324
NCI-H660	GDSC2; CTRP2	5.8814	12.1944	2.1407	10.6055

Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-15	CTRP2	-4.3901	-3.479	-4.3901	57.1724
A-253	GDSC1; GDSC2; CTRP2	-2.6421	2.069	-2.7578	42.1694

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HuTu 80	GDSC1; GDSC2	-7.9626	-5.83	-7.9626	72.065

Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Stomach Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
GSS	CTRP2	-6.7164	-4.2547	-6.7165	77.9526
NUGC-3	GDSC1; GDSC2	-6.1739	-2.6572	-6.1824	57.0862
SNU-620	CTRP2	-5.2019	-2.0055	-5.2044	67.9107
SNU-5	GDSC1; GDSC2; CTRP2	-5.1532	-3.2657	-5.1533	51.0273
SNU-16	GDSC1; GDSC2; CTRP2	-4.9357	-1.1612	-4.9459	54.3984
AGS	GDSC1; GDSC2; CTRP2; CTRP1	-4.6971	8.2803	-6.618	52.0421
ECC12	GDSC2; CTRP2	-4.5251	-3.5034	-4.5251	63.7531
HSC-39	GDSC1; GDSC2	-4.4393	-1.1632	-4.4555	46.7545
SNU-601	CTRP2	-4.2883	-0.4741	-4.3043	61.7982
RF-48	GDSC1; GDSC2	-3.9916	2.1196	-4.3664	44.6182
NCC-StC-K140	CTRP2	-3.9362	7.6974	-5.5905	55.9709
23132/87	GDSC1; GDSC2; CTRP2	-3.872	0.7082	-3.9291	48.6734
SNU-1	GDSC1; GDSC2; CTRP2	-3.3603	5.743	-4.3278	46.6714
TGBC11TKB	GDSC1; GDSC2	-3.3403	0.4295	-3.4096	40.2918
OCUM-1	GDSC1; GDSC2; CTRP2	-2.8317	3.7297	-3.2311	43.6068
NCI-N87	GDSC1; GDSC2; CTRP2	-2.3136	6.5242	-3.9248	37.7308
HGC-27	GDSC1; GDSC2; CTRP2	-1.9728	4.4238	-2.4536	39.3227
TMK-1	GDSC1; GDSC2	-1.2146	3.4911	-1.6761	30.4768
GCIY	GDSC1; GDSC2	-1.1587	2.5979	-1.3909	27.6917
SNU-668	CTRP2	0.1048	9.9079	-3.0604	33.5041
ECC10	GDSC1; GDSC2; CTRP2	1.0555	8.0113	-0.367	25.8872
MKN1	GDSC1; GDSC2; CTRP2	1.7809	10.1041	-0.5393	24.702
SNU-719	CTRP2	1.9942	8.7008	0.3101	26.2948
SK-GT-2	GDSC1; GDSC2	2.0487	6.037	0.7981	12.0644
NUGC-4	GDSC1; GDSC2; CTRP2; CTRP1	2.3167	8.7709	0.6779	20.6014
RERF-GC-1B	GDSC1; GDSC2	2.5005	13.1774	-2.3061	21.7426
IM95	GDSC1; GDSC2; CTRP2	2.8841	17.6367	-3.1318	28.5975
SCH	GDSC1; GDSC2	3.7088	7.7603	1.4163	6.9964
MKN28	GDSC1; GDSC2	3.8388	11.7235	-0.4563	13.2942
MKN74	CTRP2; CTRP1	4.9622	11.4015	1.905	14.0998
SNU-216	CTRP2	5.6078	11.9328	2.0578	11.4222
MKN45	GDSC1; GDSC2; CTRP2	5.9633	19.8791	-1.6217	19.9169
HuG1-N	CTRP2	6.5337	24.2837	-3.364	26.0081
SH-10-TC	CTRP2; CTRP1	7.2527	8.3558	4.8572	0.056
KE-39	CTRP2	7.2558	17.4405	0.5788	14.166
KATO III	GDSC1; GDSC2; CTRP2	7.3246	9.3627	4.3626	0.4156
GSU	CTRP2	7.8592	18.4405	0.5225	13.4305
LMSU	CTRP2	8.1771	19.2192	0.3675	13.4786
Fu97	GDSC1; GDSC2; CTRP2; CTRP1	8.6878	17.6628	1.5881	7.7471
Hs 746.T	GDSC1; GDSC2; CTRP2	9.2351	24.8196	-1.6059	15.4697
MKN7	GDSC1; GDSC2; CTRP2; CTRP1	9.729	18.907	1.6602	6.5
SNG-M	GDSC1; GDSC2; CTRP2; CTRP1	0.8368	20.7789	-6.464	37.8507
SNU-685	CTRP2	4.5222	19.7277	-2.7368	28.3708
SNU-1077	CTRP2	6.7596	12.1017	2.8226	6.4847

Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Thyroid Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
IHH-4	GDSC1; GDSC2	-8.35	-7.2804	-8.35	70.2748
CAL-62	GDSC1; GDSC2; CTRP2	-5.6033	-2.1605	-5.6068	58.0311
FTC-238	CTRP2	-4.3036	-2.9234	-4.3036	62.2772
SW579	CTRP2	-3.8814	7.8077	-5.57	55.7311
8505C	GDSC1; GDSC2; CTRP2	-3.6399	0.1193	-3.6611	47.3988
FTC-133	GDSC1; GDSC2; CTRP2	-3.4926	1.5173	-3.598	46.6927
KMH-2	GDSC1; GDSC2	-3.2654	2.6538	-3.6962	42.9531
CGTH-W-1	GDSC1; GDSC2; CTRP2	-2.8773	2.721	-3.0951	43.5889
ML-1 [Human leukemia]	GDSC1; GDSC2; CTRP2	-1.6096	9.9916	-3.9817	42.1501
BHT-101	GDSC1; GDSC2; CTRP2	-1.0527	11.9816	-5.0346	36.0261
B-CPAP	GDSC1; GDSC2; CTRP2	-0.5814	9.292	-2.6138	35.4454
K5	GDSC1; GDSC2	0.226	9.8583	-2.7841	28.0446
HTC-C3	GDSC1; GDSC2	1.7477	13.1463	-2.9568	25.0712
ASH-3	GDSC1; GDSC2	1.7792	9.5618	-1.1614	19.627
8305C	GDSC1; GDSC2; CTRP2	2.5652	15.1062	-2.1772	27.1937
WRO	GDSC1; GDSC2	4.2825	13.4637	-0.9724	14.3399
TT	GDSC1; GDSC2; CTRP2	5.8848	12.0742	2.203	8.5124
TT2609-C02	GDSC1; GDSC2; CTRP2	6.0527	18.815	-1.0197	18.2168

Cancer Drug Sensitivity Data Curated from 56 Cell Line(s) in Upper Aerodigestive Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
BB30-HNC	GDSC1; GDSC2	-8.5798	-6.643	-8.5798	75.9989
PCI-04B	GDSC1; GDSC2	-8.1985	-6.6018	-8.1985	73.6262
JHU-011	GDSC1; GDSC2	-8.0888	-4.0471	-8.0963	71.8425
SAS	GDSC1; GDSC2	-6.3493	-2.95	-6.3553	58.143
HO-1-N-1	GDSC1; GDSC2	-6.2944	-4.584	-6.2944	57.898
KON	GDSC1; GDSC2	-5.744	-2.3949	-5.7519	57.8481
HSC-2	GDSC1; GDSC2; CTRP2; CTRP1	-5.7423	-3.5899	-5.7423	59.2077
FaDu	GDSC1; GDSC2; CTRP2	-5.6601	-4.4368	-5.6601	58.3944
NCI-H3118	GDSC1; GDSC2	-5.5161	-0.9346	-5.5755	53.0941
BB49-HNC	GDSC1; GDSC2	-5.367	2.0104	-5.8373	51.9544
HSC-4	GDSC1; GDSC2	-5.3472	-1.1233	-5.389	52.1376
CAL-27	GDSC1; GDSC2; CTRP2	-5.2867	-3.1854	-5.2867	56.3563
PCI-06A	GDSC1; GDSC2	-5.0709	-0.8728	-5.1176	53.5279
PCI-15A	GDSC1; GDSC2	-5.0226	-0.2196	-5.1167	53.1577
CAL-33	GDSC1; GDSC2; CTRP2	-4.9906	0.6546	-5.092	54.4773
HSC-3	GDSC1; GDSC2; CTRP2	-4.684	-2.0017	-4.6848	53.0661
PE/CA-PJ49	CTRP2	-3.9114	2.4778	-4.1672	58.2594
OSC-20	GDSC1; GDSC2	-3.905	0.7865	-4.045	43.7832
YD-10B	CTRP2	-3.7787	-1.7542	-3.7798	52.4718
PE/CA-PJ15	GDSC1; GDSC2; CTRP2	-3.6148	4.2225	-4.1946	49.8843
SNU-1076	CTRP2	-3.5996	7.8576	-5.2834	54.6676
JHU-029	GDSC1; GDSC2	-3.171	5.5838	-4.4889	43.6223
BICR 22	GDSC1; GDSC2; CTRP2	-3.1532	2.7265	-3.3923	45.0585
Ca9-22	GDSC1; GDSC2	-3.0076	4.2791	-3.8689	39.9899
SCC-15	GDSC1; GDSC2	-2.3495	3.9379	-3.0461	35.9985
KOSC-2	GDSC1; GDSC2	-2.3274	4.7389	-3.2813	38.4871
BHY	GDSC1; GDSC2; CTRP2	-1.8087	7.1864	-3.1123	41.771
OSC-19	GDSC1; GDSC2	-1.6572	7.8483	-3.778	37.1729
SKN-3	GDSC1; GDSC2	-1.4622	7.4546	-3.408	34.0666
BICR 18	CTRP2	-1.4075	10.3926	-3.9369	45.7737
PE/CA-PJ34 (clone C12)	CTRP2	-1.369	4.2908	-1.7642	43.4948
JHU-022	GDSC1; GDSC2	-1.002	11.3169	-4.6736	35.2878
BICR 78	GDSC1; GDSC2	-0.9324	5.8441	-2.19	29.4491
Detroit 562	GDSC1; GDSC2; CTRP2	-0.7786	11.4841	-3.755	37.8769
PCI-38	GDSC1	-0.2272	6.9442	-3.641	18.7467
PE/CA-PJ41 (clone D2)	CTRP2	-0.1377	9.3268	-2.1637	39.2687
HO-1-u-1	GDSC1; GDSC2	0.2157	7.5755	-1.7367	25.0695
YD-8	CTRP2	0.8781	12.992	-2.7737	37.09
SCC-25	GDSC1; GDSC2; CTRP2	0.8843	9.2648	-1.0761	29.6386
SNU-899	CTRP2	1.5076	8.5995	-1.094	23.1253
PCI-30	GDSC1; GDSC2	1.5914	9.5332	-1.3221	20.5597
SNU-1214	CTRP2	1.9914	11.1314	-1.9017	24.7298
DOK	GDSC1; GDSC2	2.6207	11.0175	-1.1248	17.8011
SNU-46	CTRP2	3.2277	12.9774	-1.7643	21.2612
BICR 10	GDSC1; GDSC2	3.8148	21.3149	-5.2672	26.4807
BICR 6	CTRP2	4.0615	8.5664	2.4095	13.1161
SCC-4	GDSC1; GDSC2; CTRP2	4.3836	17.0993	-1.5422	22.2804
SAT [Human HNSCC]	GDSC1; GDSC2	4.8804	12.98	-0.2779	11.0249
BICR 56	CTRP2	4.9607	10.716	2.1386	12.3184
UPCI-SCC-090	GDSC1; GDSC2	5.7874	14.6875	-0.4604	10.3761
LB771-HNC	GDSC1; GDSC2	6.3253	19.0741	-2.2131	15.161
BICR 16	CTRP2	8.0654	17.2265	1.2499	10.6095
SCC-9	GDSC1; GDSC2; CTRP2; CTRP1	8.2651	24.4331	-2.1143	17.9021
SNU-1041	CTRP2	8.4638	15.7342	2.2091	6.6262
SNU-1066	CTRP2	8.9731	20.2468	0.4154	12.2107
BICR 31	GDSC1; GDSC2; CTRP2	9.2362	23.2596	-0.8508	15.7135

Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Urinary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
BFTC-905	GDSC1; GDSC2; CTRP2	-6.3186	-2.6375	-6.3224	61.8556
RT-4	GDSC1; GDSC2; CTRP1	-6.1994	3.263	-6.769	59.1661
647V	GDSC1; GDSC2; CTRP2	-5.7463	-4.1347	-5.7463	58.8644
639V	GDSC1; GDSC2; CTRP2	-5.5222	-2.0563	-5.5261	57.5905
CAL-29	GDSC1; GDSC2; CTRP2	-5.2641	2.1182	-5.5629	55.4574
UM-UC-3	GDSC1; GDSC2; CTRP1	-4.2836	-2.0588	-4.2838	51.3235
UM-UC-1	CTRP2	-3.1257	22.6728	-11.2485	51.3694
5637	GDSC1; GDSC2; CTRP1	-2.9059	1.5689	-2.9802	44.0109
JMSU-1	CTRP2	-2.4674	10.6677	-5.1611	50.0248
RT-112	GDSC1; GDSC2; CTRP2	-1.8025	6.4904	-2.8674	39.5
J82	GDSC1; GDSC2; CTRP2	-1.2197	4.9096	-1.7555	35.5032
VM-CUB-1	CTRP2	-0.7438	8.7829	-2.5772	42.0571
253J	CTRP2	-0.407	13.0113	-4.0612	42.5615
T24	GDSC1; GDSC2; CTRP2	0.4949	8.0824	-0.9864	30.4358
U-BLC1	CTRP2	0.5299	9.0884	-1.3674	35.4615
KU-19-19	GDSC1; GDSC2; CTRP2	1.6267	16.9828	-3.9672	32.6115
BC-3C	CTRP2	1.8567	14.643	-2.6153	34.1508
SW1710	GDSC1; GDSC2; CTRP2	2.2258	9.6225	0.1262	21.7992
SCaBER	CTRP2	3.0882	10.6266	0.4926	22.7729
253J-BV	CTRP2	3.3108	23.9003	-5.8646	35.7598
KMBC-2	CTRP2; CTRP1	4.9842	16.0708	-0.4101	22.1224
SW780	GDSC1; GDSC2	5.5974	17.4436	-1.9439	15.4045
TCCSUP	GDSC1; GDSC2; CTRP2	5.982	17.7514	-0.5457	17.0188
HT-1376	GDSC1; GDSC2; CTRP1	7.5099	13.4508	2.8121	5.1917
HT-1197	GDSC1; GDSC2; CTRP2	9.1605	23.2115	-0.8798	13.7023

Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KGN	GDSC1; GDSC2	-7.8009	-3.719	-7.8102	66.4283
SW954	GDSC1; GDSC2	-6.4222	-0.2064	-6.5972	60.7375
NEC8	GDSC1; GDSC2	-6.2857	-4.9906	-6.2857	57.8464
C-33 A	GDSC1; GDSC2	-6.0348	-0.766	-6.1298	55.9395
PA-1	GDSC1; GDSC2	-5.8535	-2.5414	-5.8603	55.1994
TC-YIK	GDSC1; GDSC2	-5.6525	-3.3497	-5.6529	54.0306
SiSo	GDSC1; GDSC2	-5.5613	-3.9988	-5.5613	53.4849
DSH1	GDSC1; GDSC2	-5.2128	-0.838	-5.2668	51.344
HEY	GDSC1; GDSC2	-4.7207	-0.0064	-4.8195	48.4884
BPH-1	GDSC1; GDSC2	-4.6626	-1.227	-4.6814	48.0929
OVCA433	GDSC1; GDSC2	-4.2715	9.6286	-7.2535	49.1969
SW962	GDSC1; GDSC2	-4.2699	3.6354	-5.051	48.8299
Ca Ski	GDSC1; GDSC2	-4.0838	2.8382	-4.6333	45.3202
C-4-I	GDSC1; GDSC2	-4.0077	2.1011	-4.3799	44.7042
ME-180	GDSC1; GDSC2	-3.8106	-0.6277	-3.8315	42.9944
HT-3	GDSC1; GDSC2	-3.0681	0.823	-3.1616	38.7254
LB831-BLC	GDSC1; GDSC2	-2.9452	2.4926	-3.3102	38.6463
ACC-OV7	GDSC1; GDSC2	-2.8956	5.1062	-4.0227	41.9375
PWR-1E	GDSC1; GDSC2	-2.6285	6.1531	-4.117	39.1066
CAL-39	GDSC1; GDSC2	-2.466	3.6047	-3.0741	36.4515
PEO1	GDSC1; GDSC2	-2.3713	5.4348	-3.5737	37.2346
DoTc2 4510	GDSC1; GDSC2	-1.5121	7.2394	-3.3697	34.1275
NT2-D1	GDSC1; GDSC2	-0.7507	5.933	-2.033	28.4901
JHOS-3	GDSC1; GDSC2	0.2129	13.3357	-4.4644	33.2629
UWB1.289	GDSC1; GDSC2	0.3997	12.0696	-3.675	31.1801
JAR	GDSC1; GDSC2	0.928	7.6038	-1.0374	22.3367
JEG-3	GDSC1; GDSC2	1.4339	25.4706	-9.3627	37.2639
OMC-1 [Human cervical carcinoma]	GDSC1; GDSC2	2.237	19.7578	-5.8167	31.3035
OVMIU	GDSC1; GDSC2	2.3272	15.6856	-3.7073	25.7855
SKN	GDSC1; GDSC2	2.9626	18.5196	-4.5784	26.5516
MS751	GDSC1; GDSC2	3.26	15.0206	-2.5791	21.0929
OVCA420	GDSC1; GDSC2	3.5211	14.5077	-2.1059	19.2476
HEC-1	GDSC1; GDSC2	3.7842	12.1006	-0.6884	14.1976
SKG-IIIa	GDSC1; GDSC2	4.0582	16.127	-2.4778	19.4036
SiHa	GDSC1; GDSC2	4.0705	6.6177	2.2485	2.9423
OV17R	GDSC1; GDSC2	5.6241	25.8646	-6.093	26.0697
NCC-IT	GDSC1; GDSC2	5.7686	16.9257	-1.5643	13.996
HeLa	GDSC1; GDSC2; CTRP2	5.8327	7.2634	4.5027	0.9263
SW756	GDSC1; GDSC2	6.9453	26.8203	-5.5612	22.4004

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Gemcitabine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Gemcitabine and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[27]

Coadministration of a Drug Treating the Disease Different from Gemcitabine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Gemcitabine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[28]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Gemcitabine and Roflumilast.	Asthma [CA23]	[27]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Gemcitabine due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[29]
Ciprofloxacin XR	DM2NLS9	Minor	Decreased absorption of Gemcitabine due to intestinal mucosa variation caused by Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[29]
Trovafloxacin	DM6AN32	Minor	Decreased absorption of Gemcitabine due to intestinal mucosa variation caused by Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[29]
Sparfloxacin	DMB4HCT	Minor	Decreased absorption of Gemcitabine due to intestinal mucosa variation caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[29]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Gemcitabine due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[29]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Gemcitabine due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[29]
ABT-492	DMJFD2I	Minor	Decreased absorption of Gemcitabine due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[29]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Gemcitabine due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[29]
Lomefloxacin	DMVRH9C	Minor	Decreased absorption of Gemcitabine due to intestinal mucosa variation caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[29]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Gemcitabine and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[30]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Gemcitabine and Cannabidiol.	Epileptic encephalopathy [8A62]	[27]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Gemcitabine and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[31]
Efavirenz	DMC0GSJ	Moderate	Increased risk of hepatotoxicity by the combination of Gemcitabine and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[32]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Gemcitabine and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[33]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Gemcitabine and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[34]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Gemcitabine and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[35]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of Gemcitabine and Methotrexate.	Leukaemia [2A60-2B33]	[27]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Gemcitabine and Denosumab.	Low bone mass disorder [FB83]	[36]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Gemcitabine and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[37]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Gemcitabine and Idelalisib.	Mature B-cell leukaemia [2A82]	[38]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Gemcitabine and Clofarabine.	Mature B-cell lymphoma [2A85]	[39]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Gemcitabine and Thalidomide.	Multiple myeloma [2A83]	[40]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Gemcitabine and Tecfidera.	Multiple sclerosis [8A40]	[41]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Gemcitabine and Siponimod.	Multiple sclerosis [8A40]	[42]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Gemcitabine and Fingolimod.	Multiple sclerosis [8A40]	[43]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Gemcitabine and Ocrelizumab.	Multiple sclerosis [8A40]	[44]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Gemcitabine and Ozanimod.	Multiple sclerosis [8A40]	[27]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Gemcitabine and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[45]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Gemcitabine due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[29]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Gemcitabine and Canakinumab.	Rheumatoid arthritis [FA20]	[46]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Gemcitabine and Rilonacept.	Rheumatoid arthritis [FA20]	[46]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Gemcitabine and Golimumab.	Rheumatoid arthritis [FA20]	[47]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Gemcitabine and Leflunomide.	Rheumatoid arthritis [FA20]	[34]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Gemcitabine when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[48]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Gemcitabine and Naltrexone.	Substance abuse [6C40]	[49]
Azathioprine	DMMZSXQ	Moderate	Additive immunosuppressive effects by the combination of Gemcitabine and Azathioprine.	Transplant rejection [NE84]	[42]
Cinoxacin	DM4EWNS	Minor	Decreased absorption of Gemcitabine due to intestinal mucosa variation caused by Cinoxacin.	Urinary tract infection [GC08]	[29]
Nalidixic acid	DMRM0JV	Minor	Decreased absorption of Gemcitabine due to intestinal mucosa variation caused by Nalidixic acid.	Urinary tract infection [GC08]	[29]
Enoxacin	DMYTE6L	Minor	Decreased absorption of Gemcitabine due to intestinal mucosa variation caused by Enoxacin.	Urinary tract infection [GC08]	[29]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Gemcitabine and Ganciclovir.	Virus infection [1A24-1D9Z]	[42]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Gemcitabine and Valganciclovir.	Virus infection [1A24-1D9Z]	[42]

References

• [1] Gemcitabine FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4793).
• [4] Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93.
• [5] BDDCS applied to over 900 drugs
• [6] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [7] FDA Approved Drug Products: GEMZAR (gemcitabine) for injection, for intravenous use
• [8] BC Cancer: Gemcitabine Monograph
• [9] Kassahun K, McIntosh I, Koeplinger K, Sun L, Talaty JE, Miller DL, Dixon R, Zajic S, Stoch SA: Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans. Drug Metab Dispos. 2014 May;42(5):818-27. doi: 10.1124/dmd.113.056580. Epub 2014 Feb 19.
• [10] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [11] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [12] A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy. Pharmacogenet Genomics. 2012 Apr;22(4):229-35. doi: 10.1097/FPC.0b013e32834e9eba.
• [13] Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug;104(8):1074-82. doi: 10.1111/cas.12186. Epub 2013 Jun 10.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [15] Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers (Basel). 2017 Nov 16;9(11).
• [16] Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia. 2010 Sep;12(9):740-7.
• [17] Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer. 2003 Jun 16;88(12):1963-70.
• [18] Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours. Br J Clin Pharmacol. 2011 Mar;71(3):437-44.
• [19] Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017 Sep 15;357(6356):1156-1160.
• [20] Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics. Drug Metab Dispos. 2008 Sep;36(9):1951-9.
• [21] Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. FEBS Open Bio. 2015 Aug 3;5:634-9.
• [22] Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat. 2007 Apr;102(2):157-72.
• [23] Reversible epigenetic regulation of 14-3-3 expression in acquired gemcitabine resistance by uhrf1 and DNA methyltransferase 1. Mol Pharmacol. 2014 Nov;86(5):561-9. doi: 10.1124/mol.114.092544. Epub 2014 Sep 4.
• [24] Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. Mol Pharmacol. 2006 Sep;70(3):1045-52. doi: 10.1124/mol.106.023333. Epub 2006 Jun 16.
• [25] Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer. 2010 Jun 29;103(1):52-60.
• [26] Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther. 2011 Jan;19(1):188-95.
• [27] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [28] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [29] Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
• [30] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [31] Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
• [32] Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
• [33] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [34] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [35] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [36] Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
• [37] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
• [38] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [39] Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
• [40] Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
• [41] Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
• [42] Cerner Multum, Inc. "Australian Product Information.".
• [43] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [44] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [45] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [46] Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
• [47] Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
• [48] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
• [49] Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.